WO2015108861A1 - Heteroaryls and uses thereof - Google Patents
Heteroaryls and uses thereof Download PDFInfo
- Publication number
- WO2015108861A1 WO2015108861A1 PCT/US2015/011191 US2015011191W WO2015108861A1 WO 2015108861 A1 WO2015108861 A1 WO 2015108861A1 US 2015011191 W US2015011191 W US 2015011191W WO 2015108861 A1 WO2015108861 A1 WO 2015108861A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- mmol
- optionally substituted
- Prior art date
Links
- 0 CC(Nc1cc(-c2cnc(C)c(N(*)S(c3ccccc3)(=O)=O)c2)ccn1)=O Chemical compound CC(Nc1cc(-c2cnc(C)c(N(*)S(c3ccccc3)(=O)=O)c2)ccn1)=O 0.000 description 7
- LXSZMGQQXZXQKX-UHFFFAOYSA-N CC1(C)OB(c2ccnc(NC(C)=O)c2)OC1(C)C Chemical compound CC1(C)OB(c2ccnc(NC(C)=O)c2)OC1(C)C LXSZMGQQXZXQKX-UHFFFAOYSA-N 0.000 description 5
- XOLJSGCMIOJJED-UHFFFAOYSA-N CC(Nc1cc(-c(cc2NCC3CC3)cnc2N)ccn1)=O Chemical compound CC(Nc1cc(-c(cc2NCC3CC3)cnc2N)ccn1)=O XOLJSGCMIOJJED-UHFFFAOYSA-N 0.000 description 2
- UZDGSLINNQQTJM-UHFFFAOYSA-N NC1(C2)CC2C1 Chemical compound NC1(C2)CC2C1 UZDGSLINNQQTJM-UHFFFAOYSA-N 0.000 description 2
- LPTVWZSQAIDCEB-UHFFFAOYSA-N Brc1cnc2[nH]ccc2c1 Chemical compound Brc1cnc2[nH]ccc2c1 LPTVWZSQAIDCEB-UHFFFAOYSA-N 0.000 description 1
- DFHAUSLTWFEZQU-UHFFFAOYSA-N C=[Br]c(cc1NCC2CC2)cnc1N Chemical compound C=[Br]c(cc1NCC2CC2)cnc1N DFHAUSLTWFEZQU-UHFFFAOYSA-N 0.000 description 1
- PWLVQVXQTFBKGU-UHFFFAOYSA-N CC(C)(C)NS(c1c(C)c(-c2ccnc(NC(C)=O)c2)cnc1Cl)(=O)=O Chemical compound CC(C)(C)NS(c1c(C)c(-c2ccnc(NC(C)=O)c2)cnc1Cl)(=O)=O PWLVQVXQTFBKGU-UHFFFAOYSA-N 0.000 description 1
- JNOKXTBOBWOWJQ-UHFFFAOYSA-N CC(C1)C=C1NC(c1cc(Br)cnc1N(C)C)=O Chemical compound CC(C1)C=C1NC(c1cc(Br)cnc1N(C)C)=O JNOKXTBOBWOWJQ-UHFFFAOYSA-N 0.000 description 1
- CQLDUJHHYOZGIT-UHFFFAOYSA-N CC(Nc(cc1-c2cnc(C)c(NS(c(ccc(F)c3)c3F)(=O)=O)c2)ncc1F)=O Chemical compound CC(Nc(cc1-c2cnc(C)c(NS(c(ccc(F)c3)c3F)(=O)=O)c2)ncc1F)=O CQLDUJHHYOZGIT-UHFFFAOYSA-N 0.000 description 1
- WIIPTFCXXCGODQ-UHFFFAOYSA-N CC(Nc1cc(-c(cc2C(N(C)C)=O)cnc2Cl)ccn1)=O Chemical compound CC(Nc1cc(-c(cc2C(N(C)C)=O)cnc2Cl)ccn1)=O WIIPTFCXXCGODQ-UHFFFAOYSA-N 0.000 description 1
- WJCIDYMLQBPVLE-UHFFFAOYSA-N CC(Nc1cc(-c(cc2C(NC3(C4)CC4C3)=O)cnc2N(C)C)ccn1)=O Chemical compound CC(Nc1cc(-c(cc2C(NC3(C4)CC4C3)=O)cnc2N(C)C)ccn1)=O WJCIDYMLQBPVLE-UHFFFAOYSA-N 0.000 description 1
- LRLXWKCKLMZDDK-UHFFFAOYSA-N CC(Nc1cc(-c(cc2C(NC3CCOCC3)=O)cnc2N)ccn1)=O Chemical compound CC(Nc1cc(-c(cc2C(NC3CCOCC3)=O)cnc2N)ccn1)=O LRLXWKCKLMZDDK-UHFFFAOYSA-N 0.000 description 1
- OOQGZYQEKGRUPJ-UHFFFAOYSA-N CC(Nc1cc(-c(cc2N3CC4CC4)cnc2NS3(=O)=O)ccn1)=O Chemical compound CC(Nc1cc(-c(cc2N3CC4CC4)cnc2NS3(=O)=O)ccn1)=O OOQGZYQEKGRUPJ-UHFFFAOYSA-N 0.000 description 1
- IANIQKYCXPGMEL-UHFFFAOYSA-N CC(Nc1cc(-c(cc2NS(c(c(F)c3)ccc3F)(=O)=O)cnc2C#N)ccn1)=O Chemical compound CC(Nc1cc(-c(cc2NS(c(c(F)c3)ccc3F)(=O)=O)cnc2C#N)ccn1)=O IANIQKYCXPGMEL-UHFFFAOYSA-N 0.000 description 1
- WWUUBABCXFRCBF-UHFFFAOYSA-N CC(Nc1cc(-c(cc2S(NC(CO)c3ccccc3)(=O)=O)cnc2Cl)ccn1)=O Chemical compound CC(Nc1cc(-c(cc2S(NC(CO)c3ccccc3)(=O)=O)cnc2Cl)ccn1)=O WWUUBABCXFRCBF-UHFFFAOYSA-N 0.000 description 1
- QOSHBDGWRQBXFE-UHFFFAOYSA-N CC(Nc1cc(-c2cnc(C)c(N(C)S(C3CC3)(=O)=O)c2)ccn1)=O Chemical compound CC(Nc1cc(-c2cnc(C)c(N(C)S(C3CC3)(=O)=O)c2)ccn1)=O QOSHBDGWRQBXFE-UHFFFAOYSA-N 0.000 description 1
- ZAJOJZOVKKCFOR-UHFFFAOYSA-N CC(Nc1cc(-c2cnc(C)c(NS(C)(=O)=O)c2)ccn1)=O Chemical compound CC(Nc1cc(-c2cnc(C)c(NS(C)(=O)=O)c2)ccn1)=O ZAJOJZOVKKCFOR-UHFFFAOYSA-N 0.000 description 1
- ZVXKOARHKANCSF-UHFFFAOYSA-N CC(Nc1cc(-c2cnc(C)c(NS(N3CCCCC3)(=O)=O)c2)ccn1)=O Chemical compound CC(Nc1cc(-c2cnc(C)c(NS(N3CCCCC3)(=O)=O)c2)ccn1)=O ZVXKOARHKANCSF-UHFFFAOYSA-N 0.000 description 1
- BQHUNRKNNADLHT-UHFFFAOYSA-N CC(Nc1cc(-c2cnc(C)c(NS(c3cc(C(F)(F)F)ccc3)(=O)=O)c2)ccn1)=O Chemical compound CC(Nc1cc(-c2cnc(C)c(NS(c3cc(C(F)(F)F)ccc3)(=O)=O)c2)ccn1)=O BQHUNRKNNADLHT-UHFFFAOYSA-N 0.000 description 1
- DAHGFDDPUBPHSV-UHFFFAOYSA-N CC(Nc1cc(-c2cnc(C)c(NS(c3cccnc3)(=O)=O)c2)ccn1)=O Chemical compound CC(Nc1cc(-c2cnc(C)c(NS(c3cccnc3)(=O)=O)c2)ccn1)=O DAHGFDDPUBPHSV-UHFFFAOYSA-N 0.000 description 1
- GFXBFNXJFQFBQA-UHFFFAOYSA-N CC(Nc1cc(-c2cncc(C(N(C)C)=O)c2)ccn1)=O Chemical compound CC(Nc1cc(-c2cncc(C(N(C)C)=O)c2)ccn1)=O GFXBFNXJFQFBQA-UHFFFAOYSA-N 0.000 description 1
- KWSSOMPPOTVGLG-UHFFFAOYSA-N CC(Nc1cc(-c2cncc(S(N3CCCC3)(=O)=O)c2)ccn1)=O Chemical compound CC(Nc1cc(-c2cncc(S(N3CCCC3)(=O)=O)c2)ccn1)=O KWSSOMPPOTVGLG-UHFFFAOYSA-N 0.000 description 1
- LFMGMKPLBDZJLP-UHFFFAOYSA-N CC(Nc1cc(Br)ccn1)=O Chemical compound CC(Nc1cc(Br)ccn1)=O LFMGMKPLBDZJLP-UHFFFAOYSA-N 0.000 description 1
- VPTIBJDHHKVLEK-UHFFFAOYSA-N CC(Nc1ncc(C)c(-c2cc(cn[nH]3)c3nc2)c1)=O Chemical compound CC(Nc1ncc(C)c(-c2cc(cn[nH]3)c3nc2)c1)=O VPTIBJDHHKVLEK-UHFFFAOYSA-N 0.000 description 1
- CZBYSMPQYZYERP-UHFFFAOYSA-N CC(Nc1nccc(-c(cc23)cnc2[O](C)=S3(N)=O)c1)=O Chemical compound CC(Nc1nccc(-c(cc23)cnc2[O](C)=S3(N)=O)c1)=O CZBYSMPQYZYERP-UHFFFAOYSA-N 0.000 description 1
- GNHGJPGCPDIRPI-UHFFFAOYSA-N CC(Nc1nccc(-c(cc23)cnc2[O](C)=S3(NC2(C3)CC3C2)=O)c1)=O Chemical compound CC(Nc1nccc(-c(cc23)cnc2[O](C)=S3(NC2(C3)CC3C2)=O)c1)=O GNHGJPGCPDIRPI-UHFFFAOYSA-N 0.000 description 1
- LMVKYSFJRVLXQV-UHFFFAOYSA-N CC(Nc1nccc(-c(cc23)cnc2[nH]cc3S(N(C)C)(=O)=O)c1)=O Chemical compound CC(Nc1nccc(-c(cc23)cnc2[nH]cc3S(N(C)C)(=O)=O)c1)=O LMVKYSFJRVLXQV-UHFFFAOYSA-N 0.000 description 1
- UCCUSZAWRXPQRP-UHFFFAOYSA-N CC(Nc1nccc(-c(cc2C(NC(N)=N)=O)cnc2N)c1)=O Chemical compound CC(Nc1nccc(-c(cc2C(NC(N)=N)=O)cnc2N)c1)=O UCCUSZAWRXPQRP-UHFFFAOYSA-N 0.000 description 1
- WBFJOMKKZPKKKS-UHFFFAOYSA-N CC(Nc1nccc(-c(cc2C(NC3CC3)=O)cnc2N)c1)=O Chemical compound CC(Nc1nccc(-c(cc2C(NC3CC3)=O)cnc2N)c1)=O WBFJOMKKZPKKKS-UHFFFAOYSA-N 0.000 description 1
- OTCIWAGIIDCOHJ-UHFFFAOYSA-N CC(Nc1nccc(-c(cc2NS(c(ccc(F)c3)c3F)(=O)=O)cnc2F)c1)=O Chemical compound CC(Nc1nccc(-c(cc2NS(c(ccc(F)c3)c3F)(=O)=O)cnc2F)c1)=O OTCIWAGIIDCOHJ-UHFFFAOYSA-N 0.000 description 1
- IXFQMTKSQIGTBI-UHFFFAOYSA-N CC(Nc1nccc(-c(cc2S(Nc(ccc(F)c3)c3F)(=O)=O)cnc2N)c1)=O Chemical compound CC(Nc1nccc(-c(cc2S(Nc(ccc(F)c3)c3F)(=O)=O)cnc2N)c1)=O IXFQMTKSQIGTBI-UHFFFAOYSA-N 0.000 description 1
- ZZBVDJUUKAGPTA-UHFFFAOYSA-N CC(Nc1nccc(-c(cc2S(Nc3ccccc3)(=O)=O)cnc2OC)c1)=O Chemical compound CC(Nc1nccc(-c(cc2S(Nc3ccccc3)(=O)=O)cnc2OC)c1)=O ZZBVDJUUKAGPTA-UHFFFAOYSA-N 0.000 description 1
- YWMPUXBINIAXBI-UHFFFAOYSA-N CC(Nc1nccc(-c2c[n]3nccc3c(NS(c(c(F)c3)ccc3F)(=O)=O)c2)c1)=O Chemical compound CC(Nc1nccc(-c2c[n]3nccc3c(NS(c(c(F)c3)ccc3F)(=O)=O)c2)c1)=O YWMPUXBINIAXBI-UHFFFAOYSA-N 0.000 description 1
- PCXGLGQSYXZXKO-UHFFFAOYSA-N CC(Nc1nccc(-c2cc(S(Nc3ccccc3)(=O)=O)c(N)nc2)c1)=O Chemical compound CC(Nc1nccc(-c2cc(S(Nc3ccccc3)(=O)=O)c(N)nc2)c1)=O PCXGLGQSYXZXKO-UHFFFAOYSA-N 0.000 description 1
- ARTRNNGIVOEYSJ-UHFFFAOYSA-N CC(Nc1nccc(-c2cnc(C)c(NS(CC(F)F)(=O)=O)c2)c1)=O Chemical compound CC(Nc1nccc(-c2cnc(C)c(NS(CC(F)F)(=O)=O)c2)c1)=O ARTRNNGIVOEYSJ-UHFFFAOYSA-N 0.000 description 1
- LZWGARNALFEHHZ-UHFFFAOYSA-N CC(Nc1nccc(-c2cnc(C)c(NS(c(cc3)ccc3OC)(=O)=O)c2)c1)=O Chemical compound CC(Nc1nccc(-c2cnc(C)c(NS(c(cc3)ccc3OC)(=O)=O)c2)c1)=O LZWGARNALFEHHZ-UHFFFAOYSA-N 0.000 description 1
- CWTLCUOLPNLRQQ-UHFFFAOYSA-N CC(Nc1nccc(-c2cnc(C)c(NS(c(ccc(F)c3)c3F)(=O)=O)c2)c1)=O Chemical compound CC(Nc1nccc(-c2cnc(C)c(NS(c(ccc(F)c3)c3F)(=O)=O)c2)c1)=O CWTLCUOLPNLRQQ-UHFFFAOYSA-N 0.000 description 1
- SCNZBXRUCAVCLV-UHFFFAOYSA-N CC(Nc1nccc(-c2cnc(C)c(NS(c(ccc(OC)c3)c3F)(=O)=O)c2)c1)=O Chemical compound CC(Nc1nccc(-c2cnc(C)c(NS(c(ccc(OC)c3)c3F)(=O)=O)c2)c1)=O SCNZBXRUCAVCLV-UHFFFAOYSA-N 0.000 description 1
- ZPWQZOMRISENBM-UHFFFAOYSA-N CC(Nc1nccc(-c2cnc(C)c(NS(c3c(C)cccc3)(=O)=O)c2)c1)=O Chemical compound CC(Nc1nccc(-c2cnc(C)c(NS(c3c(C)cccc3)(=O)=O)c2)c1)=O ZPWQZOMRISENBM-UHFFFAOYSA-N 0.000 description 1
- QORIYVMUSXHAPC-UHFFFAOYSA-N CCN(CC)C(c1cc(-c2ccnc(Nc3nc(C)ncc3)c2)cnc1C)=O Chemical compound CCN(CC)C(c1cc(-c2ccnc(Nc3nc(C)ncc3)c2)cnc1C)=O QORIYVMUSXHAPC-UHFFFAOYSA-N 0.000 description 1
- QOKCDDSHPVUDNT-UHFFFAOYSA-N CCc(cc1)ccc1S(Nc1cc(-c2ccnc(NC(C)=O)c2)cnc1C)(=O)=O Chemical compound CCc(cc1)ccc1S(Nc1cc(-c2ccnc(NC(C)=O)c2)cnc1C)(=O)=O QOKCDDSHPVUDNT-UHFFFAOYSA-N 0.000 description 1
- YYXDFWHTKOSHQT-UHFFFAOYSA-N CN(C)S(c1cc(-c2ccnc(Nc3ncc[o]3)c2)cnc1N)(=O)=O Chemical compound CN(C)S(c1cc(-c2ccnc(Nc3ncc[o]3)c2)cnc1N)(=O)=O YYXDFWHTKOSHQT-UHFFFAOYSA-N 0.000 description 1
- WSVUADXXEYJFRX-UHFFFAOYSA-N CN(C)c(c(C(O)=O)c1)ncc1Br Chemical compound CN(C)c(c(C(O)=O)c1)ncc1Br WSVUADXXEYJFRX-UHFFFAOYSA-N 0.000 description 1
- MUKADNCCYGEHQW-UHFFFAOYSA-O C[NH2+]C(NC(c1cc(-c2ccnc(Nc3ncncc3)c2)cnc1N)=O)=N Chemical compound C[NH2+]C(NC(c1cc(-c2ccnc(Nc3ncncc3)c2)cnc1N)=O)=N MUKADNCCYGEHQW-UHFFFAOYSA-O 0.000 description 1
- UBAQCDWZYMCZDA-UHFFFAOYSA-N Cc(c(-c1ccnc(NC(C2CC2)=O)c1)cnc1Cl)c1NS(c(ccc(F)c1)c1F)(=O)=O Chemical compound Cc(c(-c1ccnc(NC(C2CC2)=O)c1)cnc1Cl)c1NS(c(ccc(F)c1)c1F)(=O)=O UBAQCDWZYMCZDA-UHFFFAOYSA-N 0.000 description 1
- GQDPCLBRMGXZJR-UHFFFAOYSA-N Cc(c(C(N1CCC1)=O)c1)ncc1-c1ccnc(Nc2nc(C)ncc2)c1 Chemical compound Cc(c(C(N1CCC1)=O)c1)ncc1-c1ccnc(Nc2nc(C)ncc2)c1 GQDPCLBRMGXZJR-UHFFFAOYSA-N 0.000 description 1
- MVIMBSLOUJFIRW-UHFFFAOYSA-N Cc(c(NS(N(C)C)(=O)=O)c1)ncc1-c1ccnc(Nc2ccncn2)c1 Chemical compound Cc(c(NS(N(C)C)(=O)=O)c1)ncc1-c1ccnc(Nc2ccncn2)c1 MVIMBSLOUJFIRW-UHFFFAOYSA-N 0.000 description 1
- GMBJMXRDAOHQAS-UHFFFAOYSA-N Cc(c(NS(c(ccc(F)c1)c1F)(=O)=O)c1)ncc1-c1cc(Nc2n[n](C)cc2)ncc1 Chemical compound Cc(c(NS(c(ccc(F)c1)c1F)(=O)=O)c1)ncc1-c1cc(Nc2n[n](C)cc2)ncc1 GMBJMXRDAOHQAS-UHFFFAOYSA-N 0.000 description 1
- CIPLXZKQSYVSJN-UHFFFAOYSA-N Cc(c(NS(c(ccc(F)c1)c1F)(=O)=O)c1)ncc1-c1ccnc(NC(C2CCC2)=O)c1 Chemical compound Cc(c(NS(c(ccc(F)c1)c1F)(=O)=O)c1)ncc1-c1ccnc(NC(C2CCC2)=O)c1 CIPLXZKQSYVSJN-UHFFFAOYSA-N 0.000 description 1
- IXPHDKPSXLSOSY-UHFFFAOYSA-N Cc(c(NS(c(ccc(F)c1)c1F)(=O)=O)c1)ncc1-c1ccnc(Nc2cnccn2)c1 Chemical compound Cc(c(NS(c(ccc(F)c1)c1F)(=O)=O)c1)ncc1-c1ccnc(Nc2cnccn2)c1 IXPHDKPSXLSOSY-UHFFFAOYSA-N 0.000 description 1
- LMZBDNODHIXBMM-UHFFFAOYSA-N Cc(c(S(NC1C(C2)CC2C1)(=O)=O)c1)ncc1Cl Chemical compound Cc(c(S(NC1C(C2)CC2C1)(=O)=O)c1)ncc1Cl LMZBDNODHIXBMM-UHFFFAOYSA-N 0.000 description 1
- MRRFDSADEHQVHA-UHFFFAOYSA-N Cc1ccc(Nc2nccc(-c3cnc(C)c(NS(c(ccc(F)c4)c4F)(=O)=O)c3)c2)nn1 Chemical compound Cc1ccc(Nc2nccc(-c3cnc(C)c(NS(c(ccc(F)c4)c4F)(=O)=O)c3)c2)nn1 MRRFDSADEHQVHA-UHFFFAOYSA-N 0.000 description 1
- WLBYQJPGBDSYQF-UHFFFAOYSA-N Cc1nc(C)nc(Nc2nccc(-c(c(C)c3NS(c(ccc(F)c4)c4F)(=O)=O)cnc3Cl)c2)c1 Chemical compound Cc1nc(C)nc(Nc2nccc(-c(c(C)c3NS(c(ccc(F)c4)c4F)(=O)=O)cnc3Cl)c2)c1 WLBYQJPGBDSYQF-UHFFFAOYSA-N 0.000 description 1
- NXXDJFCUDQRLLL-UHFFFAOYSA-N Cc1nc(Nc2cc(-c3cc(C(NCC4)=O)c4nc3)ccn2)ccn1 Chemical compound Cc1nc(Nc2cc(-c3cc(C(NCC4)=O)c4nc3)ccn2)ccn1 NXXDJFCUDQRLLL-UHFFFAOYSA-N 0.000 description 1
- DNGGSVYPVVCDSO-UHFFFAOYSA-N Cc1nccc(Nc2cc(-c(cc3S(NC4CCC4)(=O)=O)cnc3Cl)ccn2)n1 Chemical compound Cc1nccc(Nc2cc(-c(cc3S(NC4CCC4)(=O)=O)cnc3Cl)ccn2)n1 DNGGSVYPVVCDSO-UHFFFAOYSA-N 0.000 description 1
- QHMRTYXFOMMFIT-UHFFFAOYSA-N Cc1nccc(Nc2cc(-c3cncc(C(N(C4)CC4(F)F)=O)c3)ccn2)n1 Chemical compound Cc1nccc(Nc2cc(-c3cncc(C(N(C4)CC4(F)F)=O)c3)ccn2)n1 QHMRTYXFOMMFIT-UHFFFAOYSA-N 0.000 description 1
- SMPFLXBOOWEHHD-UHFFFAOYSA-N Cc1nccc(Nc2nccc(-c3c[n]4nccc4c(NC(N(C4)CC4(F)F)=O)c3)c2)n1 Chemical compound Cc1nccc(Nc2nccc(-c3c[n]4nccc4c(NC(N(C4)CC4(F)F)=O)c3)c2)n1 SMPFLXBOOWEHHD-UHFFFAOYSA-N 0.000 description 1
- YFOKYPJRWYFUMH-UHFFFAOYSA-N Nc(c(S=O)c1)ncc1Br Chemical compound Nc(c(S=O)c1)ncc1Br YFOKYPJRWYFUMH-UHFFFAOYSA-N 0.000 description 1
- BAQKUNMKVAPWGU-UHFFFAOYSA-N Nc1cc(Br)ccn1 Chemical compound Nc1cc(Br)ccn1 BAQKUNMKVAPWGU-UHFFFAOYSA-N 0.000 description 1
- AZOXQBMBDRLSCQ-UHFFFAOYSA-N Nc1cc(Cl)cnc1Br Chemical compound Nc1cc(Cl)cnc1Br AZOXQBMBDRLSCQ-UHFFFAOYSA-N 0.000 description 1
- FYBCWIILJHUXBE-UHFFFAOYSA-N O=S(c(cc(cn1)Cl)c1Br)(Cl)=O Chemical compound O=S(c(cc(cn1)Cl)c1Br)(Cl)=O FYBCWIILJHUXBE-UHFFFAOYSA-N 0.000 description 1
- ZFJIXCDMHZEQIY-UHFFFAOYSA-N O=S(c(cc(cn1)Cl)c1Cl)(NC1(C2)CC2C1)=O Chemical compound O=S(c(cc(cn1)Cl)c1Cl)(NC1(C2)CC2C1)=O ZFJIXCDMHZEQIY-UHFFFAOYSA-N 0.000 description 1
- XOMWYIGZAATIGE-UHFFFAOYSA-N O=S(c1cc(Cl)cnc1Br)(NCCC1CCC1)=O Chemical compound O=S(c1cc(Cl)cnc1Br)(NCCC1CCC1)=O XOMWYIGZAATIGE-UHFFFAOYSA-N 0.000 description 1
- WVMVRXXYNPDVBK-UHFFFAOYSA-N O=S(c1cc(Cl)cnc1Cl)(Cl)=O Chemical compound O=S(c1cc(Cl)cnc1Cl)(Cl)=O WVMVRXXYNPDVBK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- Phosphatidylinositol 3-kinase is a family of lipid kinases that phosphorylate phosphatidylinositol at the 3’ position of the inositol ring.
- PI3K is comprised of several classes of genes, including Class IA, IB, II and III and some of these classes contain several isoforms (reviewed in Engelman et al., Nature Review Genetics 7:606-619 (2006)). Adding to the complexity of this family is the fact that PI3Ks function as heterodimers, comprising a catalytic domain and a regulatory domain.
- PI3K family is structurally related to a larger group of lipid and serine/threonine protein kinases known as the phosphatidylinositol 3-kinase like kinases (PIKKs), which also includes DNA-PK, ATM, ATR, mTOR, TRRAP and SMG1.
- PIKKs phosphatidylinositol 3-kinase like kinases
- Vacuolar Protein Sorting 34 is the sole Class III PI3K family member. VPS34 functions in the formation and trafficking of multiple intracellular vesicles, including vacuoles, endosomes, multivessicular bodies, lysosomes and autophagosomes (reviewed in Backer Biochem J 2008; Yan and Backer Biochem J 2007). VPS34 carries out these activities by phosphorylating PtdIns forming PtdIns3P, resulting in the recruitment and localization of a variety of FYVE and PX domain containing effector proteins that facilitate vesicular formation, elongation and movement. At a cellular level, inhibition of VPS34 results in defects in protein sorting and autophagy.
- autophagy is a regulated process whereby cells catabolize subcellular components targeted for degradation by enclosing them in double-membrane vesicles which then fuse with lysosomes.
- Autophagy has been best characterized as occurring during times of nutrient deprivation, but also plays a role in normal cellular and tissue homeostasis and functions, including the development of multiple tissue types, the immune response, clearance of neuronal aggregates and tumor suppression.
- VPS34 may also participate in several signal transduction pathways (reviewed in Backer Biochem J 2008).
- VPS34 plays an important role in many critical cellular processes including autophagy
- inhibitors of VPS34 may have therapeutic application in a number of diseases, including but not limited to cancer, muscular disorders, neurodegeneration, inflammatory disease, infectious disease and other age related illnesses (reviewed in Shintani and Klionsky Science 2004; Kondo et al Nat Rev Cancer 2005; Delgato et al Immunol Rev 2009). Therefore, it would be beneficial to provide novel VPS34 inhibitors that possess good therapeutic properties, especially for the treatment of proliferative, inflammatory, or cardiovascular disorders.
- This invention provides compounds that are inhibitors of VPS34, and accordingly can be useful for the treatment of proliferative, inflammatory, or cardiovascular disorders.
- the present invention provides a compound of formula I:
- each of R 1 and R 3 is hydrogen, 1 6 p , 0-membered cycloaliphatic, phenyl, naphthyl, 3-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; each of which being optionally substituted with 1-5 R 6 wherein:
- each R 6 independently is–CN, halo or–L 3 -R 7 wherein:
- L 3 is a bond, C 1-4 alkylene, -O-, -N(R x )-, -S-, -S(O)-, -S(O) 2 -, -C(O)-, -CO 2 -, -C(O)NR x -, -N(R x )C(O)-, -N(R x )CO 2 -, -S(O) 2 NR x -, -N(R x )S(O) 2 -, -OC(O)N(R x )-, -N(R x )C(O)N(R x ), -N(R x )S(O) 2 N(R x )- or - OC(O)-; where each R x , independently, is hydrogen or C 1-4 alkyl, and
- R 7 is hydrogen, C 1-6 aliphatic, 3-10-membered cycloaliphatic, phenyl, naphthyl, 3-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5- 10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- X is a bond or C 1-4 aliphatic;
- L 1 is -N(R 8 )C(O)-, -C(O)-N(R 9 )-, -N(R 10 )S(O) 2 -, -S(O) 2 NR 11 -, -C(O)-, -C(S)-,–S(O) 2 -, -N(R 12 )-, -O- C(O)-, -C(O)-O-, -O-S(O) 2 -, -S(O) 2 -O-, -N(R 13 )C(O)N(R 14 )-, or -N(R 15 )S(O) 2 N(R 16 )-; and wherein each of R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , and R 16 , independently, is hydrogen or C 1-4 alkyl; and
- X or L 1 can optionally join with R 1 to form an optionally substituted 5-6-membered heterocyclyl or optionally substituted 5-6-membered heteroaryl;
- R 2 is hydrogen or C 1-4 alkyl
- L 2 is a bond,–C(O)-, -S(O) 2 -, -C(O)-O-, -C(O)N(R y )-, or -S(O) 2 N(R y )-; wherein each R y , independently, is hydrogen or C 1-4 alkyl;
- each occurrence of R 4 and R 5 independently, is–CN, halo or–L 4 -R 17 wherein
- L 4 is C 1-4 alkylene, -O-, -N(R z )-, -S-, -S(O)-, -S(O) 2 -, -C(O)-, -CO 2 -, -C(O)N(R z )-, -N(R z )C(O)-, - N(R z )C(O)O-, -S(O) 2 N(R z )-, -N(R z )S(O) 2 -, -OC(O)N(R z )-, -N(R z )C(O)N(R z )-,
- R z independently, is hydrogen or C 1-4 alkyl, and R 17 is hydrogen or C 1-6 aliphatic;
- each of m and n, independently, is 0-3;
- R 4 if one R 4 is substituted at the ring carbon between the ring nitrogen and the ring carbon to which -X-L 1 -R 1 is substituted, X or L 1 can join with said R 4 to form an optionally substituted 5-7- membered heterocyclyl or an optionally substituted 5-6-membered heteroaryl; or (2) if one R 4 is substituted at either ring carbon adjacent to the ring nitrogen, said R 4 can join with the ring nitrogen to form an optionally substituted 5-7-membered heterocyclyl or an optionally substituted 5-6-membered heteroaryl; or (3) if L 2 is a bond and R 3 is phenyl, naphthyl, or heteroaryl, R 2 can join with a substituent of R 3 to form an optionally substituted 5-7-membered heterocyclyl or an optionally substituted 5-6- membered heteroaryl. Note that provisos (1), (2), and (3) are not exclusive of each other.
- exemplary -X-L 1 -R 1 moieties described herein include -X- N(R 8 )C(O)-R 1 , -X-C(O)-N(R 9 )-R 1 , -X-N(R 10 )S(O) 2 -R 1 , -X-S(O) 2 NR 11 -R 1 , -X-C(O)-R 1 , -X–S(O) 2 -R 1 , -X- N(R 12 )-R 1 , -X-O-C(O)-R 1 , -X-O-S(O) 2 -R 1 , -X-S(O) 2 -O-R 1 , -X-N(R 13 )C(O)N(R 14 )-R 1 , and -X- N(R 15 )S(O) 2 N(R 16 )-R 1 .
- the connectivity of the -L 2 - moiety should be read from right to left. That is, the first listed atom in the exemplary L 2 groups (from left) described herein is covalently bonded to the -NR 2 - moiety. Accordingly, exemplary -NR 2 -L 2 -R 3 moieties described he r ein inc l ude -NR 2 R 3 , - NR 2 -C(O)-R 3 , -NR 2 -S(O) - 2R 3 , -NR 2 -C(O )- O-R 3 , -NR 2 -C(O)N(R y )-R 3 , and -NR 2 -S(O) 2 N(R y )-R 3 .
- Other bivalent L groups should be read in similar manner.
- compounds of the invention may be optionally substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention.
- substituents such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention.
- phrase“optionally substituted” is used interchangeably with the phrase“substituted or unsubstituted.”
- the term“substituted”, whether preceded by the term“optionally” or not means that a hydrogen radical of the designated moiety is replaced with the radical of a specified substituent, provided that the substitution results in a stable or chemically feasible compound.
- substituted when used in reference to a designated atom, means that attached to the atom is a hydrogen radical, which hydrogen atom can be replaced with the radical of a suitable substituent.
- an“optionally substituted” group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
- Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
- a stable compound or chemically feasible compound is one in which the chemical structure is not substantially altered when kept at a temperature from about–80°C to about +40°, in the absence of moisture or other chemically reactive conditions, for at least a week, or a compound which maintains its integrity long enough to be useful for therapeutic or prophylactic administration to a patient.
- the phrase“one or more substituents”, as used herein, refers to a number of substituents that equals from one to the maximum number of substituents possible based on the number of available bonding sites, provided that the above conditions of stability and chemical feasibility are met.
- aromatic includes aryl and heteroaryl groups as described generally below and herein.
- aliphatic or“aliphatic group”, as used herein, means an optionally substituted straight-chain or branched C 1-12 hydrocarbon which is completely saturated or which contains one or more units of unsaturation.
- suitable aliphatic groups include optionally substituted linear or branched alkyl, alkenyl, and alkynyl groups. Unless otherwise specified, in various embodiments, aliphatic groups have 1–12, 1–10, 1–8, 1–6, 1–4, 1–3, or 1-2 carbon atoms. It is apparent to a skilled person in the art that in some embodiments, the“aliphatic” group described herein can be bivalent.
- alkyl used alone or as part of a larger moiety, refers to a saturated, optionally substituted straight or branched chain hydrocarbon group having 1–12, 1–10, 1–8, 1–6, 1–4, 1–3, or 1-2 carbon atoms.
- alkenyl used alone or as part of a larger moiety, refers to an optionally substituted straight or branched chain hydrocarbon group having at least one double bond and having 2- 12, 2-10, 2-8, 2-6, 2-4, or 2-3 carbon atoms.
- alkynyl used alone or as part of a larger moiety, refers to an optionally substituted straight or branched chain hydrocarbon group having at least one triple bond and having 2-12, 2-10, 2-8, 2-6, 2-4, or 2-3 carbon atoms.
- cycloaliphatic refers to an optionally substituted saturated or partially unsaturated cyclic aliphatic ring system having from 3 to about 14 ring carbon atoms.
- the cycloaliphatic group is an optionally substituted monocyclic hydrocarbon having 3-8 or 3-6 ring carbon atoms.
- Cycloaliphatic groups include, without limitation, optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, or cyclooctadienyl.
- cycloaliphatic also include optionally substituted bridged or fused bicyclic rings having 6-12, 6-10, or 6-8 ring carbon atoms, wherein any individual ring in the bicyclic system has 3-8 ring carbon atoms.
- cycloalkyl refers to an optionally substituted saturated ring system of about 3 to about 10 ring carbon atoms.
- exemplary monocyclic cycloalkyl rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
- cycloalkenyl refers to an optionally substituted non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having about 3 to about 10 carbon atoms.
- exemplary monocyclic cycloalkenyl rings include cyclopentyl, cyclohexenyl, and cycloheptenyl.
- halogen or“halo” means F, Cl, Br, or I.
- heteroatom refers to one or more of oxygen, sulfur, nitrogen, phosphorus, and silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro- 2H-pyrrolyl), NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl)).
- aryl and“ar-”, used alone or as part of a larger moiety e.g.,“aralkyl”, “aralkoxy”, or“aryloxyalkyl”, refer to an optionally substituted C 6–14 aromatic hydrocarbon moiety comprising one to three aromatic rings.
- the aryl group is a C 6–10 aryl group (i.e., phenyl and naphthyl).
- Aryl groups include, without limitation, optionally substituted phenyl, naphthyl, or anthracenyl.
- aryl and“ar-”, as used herein, also include groups in which an aryl ring is fused to one or more cycloaliphatic rings to form an optionally substituted cyclic structure such as a tetrahydronaphthyl, indenyl, or indanyl ring.
- aryl may be used interchangeably with the terms “aryl group”,“aryl ring”, and“aromatic ring”.
- An“aralkyl” or“arylalkyl” group comprises an aryl group covalently attached to an alkyl group, either of which independently is optionally substituted.
- the aralkyl group is C 6-10 arylC 1–6 alkyl, including, without limitation, benzyl, phenethyl, and naphthylmethyl.
- heteroaryl and“heteroar-”, used alone or as part of a larger moiety e.g., “heteroaralkyl”, or“heteroaralkoxy”, refer to groups having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms; having 6, 10, or 14 electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms.
- a heteroaryl group may be mono-, bi-, tri-, or polycyclic, for example, mono-, bi-, or tricyclic (e.g., mono- or bicyclic).
- heteroatom refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.
- a nitrogen atom of a heteroaryl may be a basic nitrogen atom and may also be optionally oxidized to the corresponding N-oxide.
- a heteroaryl is substituted by a hydroxy group, it also includes its corresponding tautomer.
- the terms“heteroaryl” and“heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocycloaliphatic rings.
- heteroaryl groups include thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, pteridinyl, indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl
- heteroaryl may be used interchangeably with the terms “heteroaryl ring”,“heteroaryl group”, or“heteroaromatic”, any of which terms include rings that are optionally substituted.
- heteroarylkyl refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
- heterocycle As used herein, the terms“heterocycle”,“heterocyclyl”,“heterocyclic radical”, and “heterocyclic ring” are used interchangeably and refer to a stable 3- to 8-membered monocyclic or 7–10- membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, such as one to four, heteroatoms, as defined above.
- nitrogen includes a substituted nitrogen.
- the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR + (as in N-substituted pyrrolidinyl).
- a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
- saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and thiamorpholinyl.
- a heterocyclyl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic.
- the term“heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
- a heterocyclic ring also includes groups in which the heterocyclic ring is fused to one or more aryl rings.
- the term“partially unsaturated” refers to a ring moiety that includes at least one double or triple bond between ring atoms.
- the term“partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aromatic (e.g., aryl or heteroaryl) moieties, as herein defined.
- alkylene refers to a bivalent alkyl group.
- An "alkylene chain” is a polymethylene group, i.e., -(CH 2 ) n -, wherein n is a positive integer, e.g., from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3.
- An optionally substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms is optionally replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group and also include those described in the specification herein. It will be appreciated that two substituents of the alkylene group may be taken together to form a ring system. In certain embodiments, two substituents can be taken together to form a 3-7-membered ring. The substituents can be on the same or different atoms.
- An alkylene chain also can be optionally interrupted by a functional group.
- An alkylene chain is "interrupted" by a functional group when an internal methylene unit is interrupted or replaced by the functional group. Examples of suitable "interrupting functional groups" are described in the specification and claims herein.
- An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents and thus may be“optionally substituted”.
- suitable substituents on the unsaturated carbon atom of an aryl group e.g., phenyl or naphthyl
- heteroaryl group e.g., pyridyl
- An aliphatic or heteroaliphatic group, or a non-aromatic carbocyclic or heterocyclic ring may contain one or more substituents and thus may be“optionally substituted”.
- substituents on the nitrogen of a non-aromatic heterocyclic ring also include and are generally selected from
- a ring nitrogen atom of a heteroaryl or non-aromatic heterocyclic ring also may be oxidized to form the corresponding N-hydroxy or N-oxide compound.
- a nonlimiting example of such a heteroaryl having an oxidized ring nitrogen atom is N-oxidopyridyl.
- two independent occurrences of R + are taken together with their intervening atom(s) to form a monocyclic or bicyclic ring selected from 3–13-membered cycloaliphatic, 3–12-membered heterocyclyl having 1–5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 6–10-membered aryl, or 5–10-membered heteroaryl having 1–5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Exemplary rings that are formed when two independent occurrences of R + (or any other variable similarly defined in the specification and claims herein), are taken together with their intervening atom(s) include, but are not limited to the following: a) two independent occurrences of R + (or any other variable similarly defined in the specification or claims herein) that are bound to the same atom and are taken together with that atom to form a ring, for example, N(R + ) 2 , where both occurrences of R + are taken together with the nitrogen atom to form a piperidin-1-yl, piperazin-1-yl, or morpholin-4-yl group; and b) two independent occurrences of R + (or any other variable similarly defined in the specification or claims herein) that are bound to different atoms and are taken together with both of those atoms to form a ring,
- OR + for example where a phenyl group is substituted with two occurrences of OR + OR +
- structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
- structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
- compounds having the present structures where there is a replacement of hydrogen by deuterium or tritium, or a replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
- Such compounds are useful, as a nonlimiting example, as analytical tools or probes in biological assays.
- the present invention encompasses one enantiomer of inhibitor free from the corresponding optical isomer, racemic mixture of the inhibitor and mixtures enriched in one enantiomer relative to its corresponding optical isomer.
- the mixture contains, for example, an enantiomeric excess of at least 50%, 75%, 90%, 95% 99% or 99.5%.
- the enantiomers of the present invention may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts which may be separated, for example, by crystallization; formation of diastereoisomeric derivatives or complexes which may be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic esterification; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support for example silica with a bound chiral ligand or in the presence of a chiral solvent.
- enantiomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer into the other by asymmetric transformation.
- the present invention encompasses a diastereomer free of other diastereomers, a pair of diastereomers free from other diasteromeric pairs, mixtures of diasteromers, mixtures of diasteromeric pairs, mixtures of diasteromers in which one diastereomer is enriched relative to the other diastereomer(s) and mixtures of diasteromeric pairs in which one diastereomeric pair is enriched relative to the other diastereomeric pair(s).
- the mixture is enriched in one diastereomer or diastereomeric pair(s) relative to the other diastereomers or diastereomeric pair(s), the mixture is enriched with the depicted or referenced diastereomer or diastereomeric pair(s) relative to other diastereomers or diastereomeric pair(s) for the compound, for example, by a molar excess of at least 50%, 75%, 90%, 95%, 99% or 99.5%.
- the diastereoisomeric pairs may be separated by methods known to those skilled in the art, for example chromatography or crystallization and the individual enantiomers within each pair may be separated as described above. Specific procedures for chromatographically separating diastereomeric pairs of precursors used in the preparation of compounds disclosed herein are provided the examples herein. 3. Brief Description of the Drawings
- Figure 1 is a graph showing the effect of treatment with a compound of formula I (I-41) and erlotinib when administered orally (po) daily (qd) as single agents and in combination to nude female mice bearing human colorectal adenocarcinoma SW48 tumor xenografts.
- Figure 2 is a graph showing the effect of treatment with a compound of formula I (I-41) and erlotinib when administered orally (po) daily (qd) as single agents and in combination to nude female mice bearing human non-small cell lung PC9 tumor xenografts.
- Figure 3 is a graph showing the effect of treatment with a compound of formula I (I-41) and erlotinib when administered orally (po) daily (qd) as single agents and in combination to nude female mice bearing human non-small cell lung NCI H1650 tumor xenografts.
- Figure 4 is a graph showing the effect of treatment with a compound of formula I (I-41) and afatinib when administered orally (po) daily (qd) as single agents and in combination to nude female mice bearing human non-small cell lung NCI-H1975 tumor xenografts.
- Figure 5 is a graph showing the effect of treatment with a compound of formula I (I-299) and erlotinib when administered orally (po) daily (qd) as single agents and in combination to nude female mice bearing human non-small cell lung PC9 tumor xenografts.
- Figure 6 is a graph showing the effect of treatment with a compound of formula I (I-299) and erlotinib when administered orally (po) daily (qd) as single agents and in combination to nude female mice bearing human non-small cell lung NCI H1650 tumor xenografts. 4. Description of Exemplary Compounds:
- the present invention provides a compound of formula I:
- each of R 1 and R 3 is hydrogen, C 1-6 aliphatic, 3-10-membered cycloaliphatic, phenyl, naphthyl, 3-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; each of which being optionally substituted with 1-5 R 6 wherein:
- each R 6 independently is–CN, halo or–L 3 -R 7 wherein:
- L 3 is a bond, C 1-4 alkylene, -O-, -N(R x )-, -S-, -S(O)-, -S(O) 2 -, -C(O)-, -CO 2 -, -C(O)NR x -, -N(R x )C(O)-, -N(R x )CO 2 -, -S(O) 2 NR x -, -N(R x )S(O) 2 -, -OC(O)N(R x )-, -N(R x )C(O)N(R x ), -N(R x )S(O) 2 N(R x )- or - OC(O)-; where each R x , independently, is hydrogen or C 1-4 alkyl, and R 7 is hydrogen, C 1-6 aliphatic, 3-10-membered cycloaliphatic,
- X is a bond or C 1-4 aliphatic
- L 1 is -N(R 8 )C(O)-, -C(O)-N(R 9 )-, -N(R 10 )S(O) 2 -, -S(O) 2 NR 11 -, -C(O)-, -C(S)-,–S(O) 2 -, -N(R 12 )-, -O- C(O)-, -C(O)-O-, -O-S(O) 2 -, -S(O) 2 -O-, -N(R 13 )C(O)N(R 14 )-, or -N(R 15 )S(O) 2 N(R 16 )-; and wherein each of R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , and R 16 , independently, is hydrogen or C 1-4 alkyl; and X or L 1 can optionally join with R 1 to form an optionally
- R 2 is hydrogen or C 1-4 alkyl
- L 2 is a bond,–C(O)-, -S(O) 2 -, -C(O)-O-, -C(O)N(R y )-, or -S(O) 2 N(R y )-; wherein each R y , independently, is hydrogen or C 1-4 alkyl;
- each occurrence of R 4 and R 5 independently, is–CN, halo or–L 4 -R 17 wherein
- L 4 is C 1-4 alkylene, -O-, -N(R z )-, -S-, -S(O)-, -S(O) 2 -, -C(O)-, -CO 2 -, -C(O)N(R z )-, -N(R z )C(O)-, - N(R z )C(O)O-, -S(O) 2 N(R z )-, -N(R z )S(O) 2 -, -OC(O)N(R z )-, -N(R z )C(O)N(R z )-,
- R z independently, is hydrogen or C 1-4 alkyl, and R 17 is hydrogen or C 1-6 aliphatic;
- each of m and n, independently, is 0-3;
- R 4 if one R 4 is substituted at the ring carbon between the ring nitrogen and the ring carbon to which -X-L 1 -R 1 is substituted, X or L 1 can join with said R 4 to form an optionally substituted 5-7- membered heterocyclyl or an optionally substituted 5-6-membered heteroaryl; or (2) if one R 4 is substituted at either ring carbon adjacent to the ring nitrogen, said R 4 can join with the ring nitrogen to form an optionally substituted 5-7-membered heterocyclyl or an optionally substituted 5-6-membered heteroaryl; or (3) if L 2 is a bond and R 3 is phenyl, naphthyl, or heteroaryl, R 2 can join with a substituent of R 3 to form an optionally substituted 5-7-membered heterocyclyl or an optionally substituted 5-6- membered heteroaryl. Note that provisos (1), (2), and (3) are not exclusive of each other.
- the invention provides a compound of formula I:
- each of R 1 and R 3 is hy -10-membered cycloaliphatic, phenyl, naphthyl, 3-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; each of which being optionally substituted with 1-5 R 6 wherein:
- each R 6 independently is–CN, halo or–L 3 -R 7 wherein:
- L 3 is a bond, C 1-4 alkylene, -O-, -N(R x )-, -S-, -S(O)-, -S(O) 2 -, -C(O)-, -CO 2 -, -C(O)NR x -, -N(R x )C(O)-, -N(R x )CO 2 -, -S(O) 2 NR x -, -N(R x )S(O) 2 -, -OC(O)N(R x )-, -N(R x )C(O)N(R x ), -N(R x )S(O) 2 N(R x )- or - OC(O)-; where each R x , independently, is hydrogen or C 1-4 alkyl, and
- R 7 is hydrogen, C 1-6 aliphatic, 3-10-membered cycloaliphatic, phenyl, naphthyl, 3-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5- 10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- X is a bond or C 1-4 aliphatic
- L 1 is -N(R 8 )C(O)-, -C(O)-N(R 9 )-, -N(R 10 )S(O) 2 -, -S(O) 2 NR 11 -, -C(O)-,–S(O) 2 -, -N(R 12 )-, -O-C(O)-, - C(O)-O-, -O-S(O) 2 -, -S(O) 2 -O-, -N(R 13 )C(O)N(R 14 )-, or -N(R 15 )S(O) 2 N(R 16 )-; and wherein each of R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , and R 16 , independently, is hydrogen or C 1-4 alkyl; and X or L 1 can optionally join with R 1 to form an optionally substituted 5-6-membered
- R 2 is hydrogen or C 1-4 alkyl
- L 2 is a bond,–C(O)-, -S(O) 2 -, -C(O)-O-, -C(O)N(R y )-, or -S(O) 2 N(R y )-; wherein each R y , independently, is hydrogen or C 1-4 alkyl;
- each occurrence of R 4 and R 5 is–CN, halo or–L 4 -R 17 wherein L 4 is C 1-4 alkylene, -O-, -N(R z )-, -S-, -S(O)-, -S(O) 2 -, -C(O)-, -CO 2 -, -C(O)N(R z )-, -N(R z )C(O)-, - N(R z )C(O)O-, -S(O) 2 N(R z )-, -N(R z )S(O) 2 -, -OC(O)N(R z )-, -N(R z )C(O)N(R z )-,
- R z independently, is hydrogen or C 1-4 alkyl, and R 17 is hydrogen or C 1-6 aliphatic;
- each of m and n, independently, is 0-3;
- R 4 is substituted at the ring carbon between the ring nitrogen and the ring carbon to which -X-L 1 -R 1 is substituted, X or L 1 can join with said R 4 to form an optionally substituted 5- 7-membered heterocyclyl or an optionally substituted 5-6-membered heteroaryl.
- R 1 is H.
- R 1 is C 1-6 aliphatic, 3-10-membered cycloaliphatic, phenyl, naphthyl, 3-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; each of which is optionally substituted with 1-5 R 6 .
- R 1 is C 1-3 alkyl.
- R 3 is C 1-6 aliphatic, 3-6- membered cycloaliphatic, phenyl, naphthyl, 3-6-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-6-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.
- X or L 1 optionally joins with R 1 to form an optionally substituted 5-6- membered heterocyclyl or an optionally substituted 5-6-membered heteroaryl. In other embodiments, X joins with R 1 to form an optionally substituted 5-6-membered heterocyclyl. In other embodiments, L 1 joins with R 1 to form an optionally substituted 5-6-membered heterocyclyl. In some embodiments, R 1 and R 10 join together to form an optionally substituted 5-6-membered heterocyclyl. In other embodiments, X joins with R 1 to form an optionally substituted 5-6-membered heteroaryl.
- L 1 joins with R 1 to form an optionally substituted 5-6-membered heteroaryl.
- R 1 and R 11 join together to form an optionally substituted 5-6-membered heteroaryl.
- said heterocyclyl and heteroaryl are as defined above (e.g., each can be optionally substituted as described above and e.g., each heteroaryl can contain heteroatom nitrogen, oxygen, or sulfur, including oxidized form of nitrogen or sulfur).
- said 5-6- membered heterocyclyl or 5-6-membered heteroaryl is unsubstituted.
- said 5- 6-membered heterocyclyl or 5-6-membered heteroaryl is substituted (e.g., comprises 1, 2, 3, 4, or 5 substituent groups such as those described for R 6 herein); in some embodiments, said substituents are independently -halo, -CN, -C 1-6 aliphatic, -OH, and–O-(C 1-6 aliphatic). In certain embodiments, two substituent groups of said 5-6-membered heterocyclyl or 5-6-membered heteroaryl combine to form an optionally substituted phenyl group or an optionally substituted 5-6-membered heteroaryl group.
- R 1 is C 1-4 alkyl, 3-6-membered cycloaliphatic, phenyl, naphthyl, 3-6- membered heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur.
- R 1 is a C 1-6 aliphatic. In other embodiments, R 1 is a C 1-6 alkyl. In certain embodiments, R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, or n-hexyl.
- R 1 is methyl, cyclohexyl, pyridyl, phenyl, or naphthyl.
- R 1 is
- R 1 is a 3-, 4-, 5-, or 6-membered cycloaliphatic. In other embodiments, R 1 is a 5-to-10-membered bridged cycloaliphatic. In other embodiments, R 1 is a 3-, 4-, 5-, or 6-membered heterocyclyl having 1-4, 1-3, or 1-2 heteroatoms independently selected form nitrogen, oxygen, or sulfur. In other embodiments, R 1 is a 5-6-membered heteroaryl. In other embodiments, R 1 is phenyl. In other embodiments, R 1 is naphthyl.
- R 1 is unsubstituted. In other embodiments, R 1 is substituted with 1, 2, 3, 4, or 5 R 6 as described herein. In some embodiments, R 1 is optionally substituted with 1-3 R 6 wherein each R 6 independently is halo or–L 3 -R 7 . In some embodiments, L 3 is a bond, C 1-3 alkylene, -O-, or -N(R x )-.
- R 7 is hydrogen, 3-6-membered cycloaliphatic, phenyl, 3-6-membered heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-6- membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur .
- R 1 is optionally substituted with 1-3 R 6 , wherein each R 6 independently is fluoro, chloro, C 1-4 aliphatic, trifluoromethyl, hydroxyl or -O-C 1-4 aliphatic.
- R 1 is optionally substituted cyclopropyl, methyl, ethyl, isopropyl, -(CH 2 ) 2 OCH 2 CH 3 , optionally substituted phenyl (e.g., 2,4-difluorophenyl, 2,4-dichlorophenyl, 4-ethylphenyl, 2-methoxy-4-fluorophenyl, 3,4-difluorophenyl, 2,3-difluorophenyl, 2- trifluoromethylphenyl, 3-tert-butylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 2-fluoro-4-methylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,5- dichlorophenyl, 2-methoxy-4-methylphenyl, 2-chloro-4-methylphenyl
- phenyl e
- R 3 is H.
- R 3 is C 1-6 aliphatic, 3-10-membered cycloaliphatic, phenyl, naphthyl, 3-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; each of which is optionally substituted with 1-5 R 6 .
- R 3 is C 1-3 alkyl.
- R 3 is C 1-6 aliphatic, 3-6-membered cycloaliphatic, phenyl, naphthyl, 3-6-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-6-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.
- R 3 is C 1-3 aliphatic, C 3-6 cycloaliphatic, or 5-10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, said cycloaliphatic or heteroaryl being optionally substituted with 1-5 R 6 .
- R 3 is methyl, cyclopropyl, or 6-membered heteroaryl that is optionally substituted with 1-2 R 6 .
- R 3 is 4-pyrimidinyl comprising optional substituents independently selected from methyl, methoxy, cyano, trifluoromethyl, and cyclopropyl (e.g., comprising 1, 2, or 3 optionally substituents independently selected from methyl, methoxy, cyano, trifluoromethyl, and cyclopropyl).
- R 3 is C 1-3 aliphatic.
- R 3 is C 1-3 alkyl (e.g., methyl, ethyl, n-propyl, or iso-propyl). In other embodiments, R 3 is methyl.
- R 3 is C 3-6 cycloaliphatic (e.g., cyclopropyl).
- R 3 is 5-10-membered heteroaryl (e.g., 6-membered heteroaryl) having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.
- R 3 is pyridinyl, pyrimidinyl, pyrazolyl, imidazolyl, benzoxazolyl, benzthiazolyl, 1,8-naphthyridinyl, quinolinyl, or isoquinolinyl.
- R 3 is pyridyl or pyrimidinyl.
- R 3 is pyridinyl, pyrimidinyl, pyrazolyl, imidazolyl, benzoxazolyl, benzthiazolyl, 1,8-naphthyridinyl, quinolinyl, or isoquinolinyl; each of which being optionally substituted with C 1-6 aliphatic, C 1-6 alkoxy, or cyano.
- R 3 is unsubstituted. In other embodiments, R 3 is substituted with 1, 2, 3, 4, or 5 (e.g., 1 or 2) R 6 as described herein.
- R 6 is C 1-6 aliphatic (e.g., methyl or trifluoromethyl), C 1-6 alkoxy (e.g., methoxy), cyano, or cyclopropyl.
- R 3 is
- R 3 is selected from those depicted in Table 1, below.
- each R 6 independently is halo or -L 3 -R 7 .
- L 3 is a bond.
- L 3 is C 1-4 alkylene, -O-, -N(R x )-, - S-, -S(O)-, -S(O) 2 -, -C(O)-, -CO 2 -, -C(O)NR x -, -N(R x )C(O)-, -N(R x )CO 2 -, -S(O) 2 NR x -, -N(R x )S(O) 2 -, - OC(O)N(R x )-, -N(R x )C(O)N(R x ), -N(R x )S(O) 2 N(R x )- or -OC(O)-.
- L 3 is a bond, C 1-3 alkylene, -O-, or -N(R
- R x is hydrogen. In other embodiments, R x is unsubstituted C 1-4 alkyl. In other embodiments, R x is substituted C 1-4 alkyl. In some embodiments, the substituent groups are selected from the exemplary substituent groups described herein for aliphatic groups; optionally, said substituted C 1-4 alkyl has 1, 2, 3, 4, or 5 substituents. In some embodiments, said alkyl includes a substituent selected from: a 3-, 4-, 5-, or 6-membered cycloaliphatic; 3-, 4-, 5-, or 6-membered heterocyclyl, -OH, -O-(C 1-6 aliphatic), optionally substituted amino, and -halo.
- R 7 is hydrogen. In other embodiments, R 7 is C 1-6 aliphatic, 3-10- membered cycloaliphatic, phenyl, naphthyl, 3-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In still other embodiments, R 7 is hydrogen, 3-6-membered cycloaliphatic, phenyl, 3-6-membered heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur.
- R 7 is unsubstituted.
- the substituent groups are selected from the exemplary substituent groups described herein for aliphatic, cycloaliphatic, heterocyclyl, heteroaryl, and aryl moieties.
- optional substituents for aryl also apply to phenyl and naphthyl.
- said R 7 has 1, 2, 3, 4, or 5 substituents.
- the substituent groups are selected from C 1-6 alkyl, -OH, optionally substituted amino, halo, and -O-(C 1-6 aliphatic).
- each R 6 independently is halo or–L 3 -R 7 wherein L 3 is a bond, C 1-3 alkylene, -O-, or -N(R x )- and R 7 is hydrogen, 3-6-membered cycloaliphatic, phenyl 3-6-membered heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-6- membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur.
- each R 6 independently is fluoro, chloro, C 1-4 aliphatic, trifluoromethyl, hydroxyl or -O-C 1-4 aliphatic. In some embodiments, R 6 is selected from those depicted in Table 1, below.
- X is a bond. In other embodiments, X is C 1-4 alkylene. In still other embodiments, X is methylene or ethylene. In some embodiments, X is selected from those depicted in Table 1, below.
- X joins with said R 4 to form an optionally substituted 5-7-membered (e.g., 5-6-membered) heterocyclyl or an optionally substituted 5-6-membered heteroaryl.
- Said heterocyclyl and heteroaryl are as defined above (e.g., each can be optionally substituted as described above and e.g., each heteroaryl can contain heteroatom nitrogen, oxygen, or sulfur, including oxidized form of nitrogen or sulfur).
- X joins with said R 4 to form an optionally substituted pyrazolyl, imidazolyl, pyrrolyl, triazolyl, oxazolyl, or thiazolyl. In other embodiments, X joins with said R 4 to form any of the embodiments in Table 1, below.
- X joins with R 1 to form an optionally substituted 5-6-membered heterocyclyl or 5-6-membered heteroaryl. In still other embodiments, X joins with R 1 to form an optionally substituted 5-6-membered heterocyclyl. In certain embodiments, X joins with R 1 to form an optionally substituted 5-6-membered heteroaryl.
- said heterocyclyl and heteroaryl are as defined above (e.g., each can be optionally substituted as described above and e.g., each heteroaryl can contain heteroatom nitrogen, oxygen, or sulfur, including oxidized form of nitrogen or sulfur).
- said 5-6-membered heterocyclyl or 5-6-membered heteroaryl is unsubstituted.
- said 5-6-membered heterocyclyl or 5-6-membered heteroaryl is substituted (e.g., comprises 1, 2, 3, 4, or 5 substituent groups such as those described for R 6 herein); in some embodiments, said substituents are independently -halo, -CN, -C 1-6 aliphatic, -OH, and–O-(C 1-6 aliphatic).
- two substituent groups of said 5-6-membered heterocyclyl or 5-6- membered heteroaryl combine to form an optionally substituted phenyl group or an optionally substituted 5-6-membered heteroaryl group.
- X joins with said R 1 to form any of the embodiments in Table 1, below.
- L 1 is -N(R 8 )C(O)-, -N(R 10 )S(O) 2 -, -C(O)-, or -S(O) 2 -. In some embodiments, L 1 is -N(R 8 )C(O)-, -N(R 10 )S(O) 2 -, or -S(O) 2 -. In some embodiments, L 1 is -N(R 10 )S(O) 2 -. In some embodiments, L 1 is -C(O)-.
- any of R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , and R 16 is hydrogen.
- any of R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , and R 16 is C 1-4 alkyl.
- each of R 8 and R 10 independently, is hydrogen, methyl or ethyl.
- R 10 is hydrogen, methyl or ethyl.
- any of R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , and R 16 independently, is selected from those depicted in Table 1, below.
- L 1 is -N(R 10 )S(O) 2 -, and R 10 is hydrogen, methyl or ethyl.
- L 1 joins with R 1 to form an optionally substituted 5-6-membered heterocyclyl or optionally substituted 5-6-membered heteroaryl. In certain embodiments, L 1 joins with R 1 to form an optionally substituted 5-6-membered heterocyclyl. In certain embodiments, L 1 joins with R 1 to form an optionally substituted 5-6-membered heteroaryl. In some embodiments, R 10 and R 1 join together to form an optionally substituted 5-6-membered heterocyclyl. In some embodiments, R 11 and R 1 join together to form an optionally substituted 5-6-membered heteroaryl.
- heterocyclyl and heteroaryl are as defined above (e.g., each can be optionally substituted as described above and e.g., each heteroaryl can contain heteroatom nitrogen, oxygen, or sulfur, including oxidized form of nitrogen or sulfur).
- said 5-6-membered heterocyclyl or 5-6-membered heteroaryl is unsubstituted.
- said 5-6-membered heterocyclyl or 5-6-membered heteroaryl is substituted (e.g., comprises 1, 2, 3, 4, or 5 substituent groups such as those described for R 6 herein); in some embodiments, said substituents are independently -halo, -CN, -C 1-6 aliphatic, -OH, and -O-(C 1-6 aliphatic). In certain embodiments, two substituent groups of said 5-6-membered heterocyclyl or 5-6-membered heteroaryl combine to form an optionally substituted phenyl group or an optionally substituted 5-6-membered heteroaryl group.
- L 1 joins with said R 4 to form an optionally substituted 5-6-membered heterocyclyl or an optionally substituted 5-6-membered heteroaryl.
- L 1 joins with said R 4 to form an optionally substituted pyrazolyl, imidazolyl, pyrrolyl, triazolyl, oxazolyl, or thiazolyl.
- X is a bond.
- R 2 is hydrogen. In other embodiments, R 2 is C 1-4 alkyl (e.g., methyl, ethyl, or cyclopropylmethyl). In certain embodiments, R 2 is hydrogen, methyl, ethyl, or cyclopropylmethyl. In some embodiments, R 2 is selected from those depicted in Table 1, below.
- L 2 is a bond.
- R 3 is phenyl, naphthyl, or heteroaryl (e.g., pyridinyl or pyrimidinyl)
- R 2 can join with a substituent of R 3 to form an optionally substituted 5-7-membered heterocyclyl (e.g., piperidinyl or piperazinyl) or an optionally substituted 5-6-membered heteroaryl (e.g., imidazolyl , pyrazolyl, or pyridinyl).
- L 2 is–C(O)-, -S(O) 2 -, -C(O)-O-, -C(O)N(R y )-, or -S(O) 2 N(R y )-. In other embodiments, L 2 is–C(O)- or -C(O)-O-. In certain embodiments, L 2 is–C(O)-. In other embodiments, L 2 is a bond, -C(O)- or -C(O)-O-. In still other embodiments, L 2 is a bond or–C(O)-. In some embodiments, L 2 is selected from those depicted in Table 1, below.
- any R y is hydrogen. In some embodiments, any R y is C 1-4 alkyl. In some embodiments, R y is selected from those depicted in Table 1, below.
- m is 0. In other embodiments, m is 1, 2, or 3. In other embodiments, m is 0, 1, or 2 (e.g., m is 1 or 2).
- the R 4 groups may be located at any position of the pyridyl ring having the–X-L 1 -R 1 moiety. That is, any R 4 can be located at either carbon ortho to the pyridyl nitrogen, as well as the carbon para to the pyridyl nitrogen.
- R 4 is–CN, halo or–L 4 -R 17 . In some embodiments, R 4 is halo or–L 4 - R 17 .
- R 4 is substituted at the ring carbon between the ring nitrogen and the ring carbon to which -X-L 1 -R 1 is substituted.
- X or L 1 joins with said R 4 to form an optionally substituted 5-7-membered heterocyclyl or 5-6-membered heteroaryl.
- X joins with said R 4 to form an optionally substituted 5-7-membered heterocyclyl.
- X joins with said R 4 to form an optionally substituted 5-6-membered heteroaryl.
- L 1 joins with said R 4 to form an optionally substituted 5-7-membered heterocyclyl.
- L 1 joins with said R 4 to form an optionally substituted 5-6-membered heteroaryl.
- said heterocyclyl and heteroaryl are as defined above (e.g., each can be optionally substituted as described above and e.g., each heteroaryl can contain heteroatom nitrogen, oxygen, or sulfur, including oxidized form of nitrogen or sulfur).
- said 5-7-membered heterocyclyl or 5-6-membered heteroaryl is unsubstituted.
- said 5-7-membered heterocyclyl or 5-6-membered heteroaryl is substituted (e.g., comprises 1, 2, 3, 4, or 5 substituent groups such as those described for R 6 herein); in some embodiments, said substituents are independently - halo, -CN, -C 1-6 aliphatic, -OH, and–O-(C 1-6 aliphatic). In certain embodiments, two substituent groups of said 5-6-membered heterocyclyl or 5-6-membered heteroaryl combine to form an optionally substituted phenyl group or an optionally substituted 5-6-membered heteroaryl group.
- R 4 is substituted at the ring carbon between the ring nitrogen and the ring carbon to which -X-L 1 -R 1 is substituted, and a second R 4 is substituted at the para position with respect to the ring nitrogen.
- R 4 is halo or–L 4 -R 17 .
- L 4 is C 1-4 alkylene chain, -O-, or -N(R z )-.
- R 4 is independently halo or C 1-3 alkyl.
- R z is hydrogen. In other embodiments, R z is C 1-4 alkyl. In further embodiments, R z is hydrogen or methyl.
- R 17 is hydrogen. In other embodiments, R 17 is C 1-6 aliphatic. In still other embodiments, R 17 is hydrogen or C 1-3 alkyl.
- R 4 is fluoro, chloro, C 1-3 alkyl, trifluoromethyl, hydroxyl,–NH 2 or -NH-C 1-3 alkyl. In still other embodiments, R 4 is fluoro, chloro, unsubstituted C 1-3 aliphatic, trifluoromethyl, hydroxyl, methoxy,–NH 2 or–NH-C 1-3 aliphatic. In some embodiments, R 4 is selected from those depicted in Table 1, below. In further embodiments, m is 0-2. In some embodiments, one R 4 is substituted at the ring carbon between the ring nitrogen and the ring carbon to which–X-L 1 -R 1 is substituted.
- m is 2 and a second R 4 is substituted at the para position with respect to the ring nitrogen.
- each of the two R 4 i.e., the R 4 that is substituted at the ring carbon between the ring nitrogen and the ring carbon to which–X-L 1 -R 1 is attached, and the second R 4 substituted at the para position with respect to the ring nitrogen is independently fluoro, chloro, or methyl.
- said second R 4 is fluoro, chloro, methyl, or methoxy.
- n is 0. In other embodiments, n is 1, 2, or 3. In other embodiments, n is 0, 1, or 2.
- the R 5 groups may be located at any position of the pyridyl ring having the–NR 2 -L 2 -R 3 moiety. That is, any R 5 can be located at either carbon meta to the pyridyl nitrogen, as well as the carbon ortho to the pyridyl nitrogen.
- R 5 is halo or–L 4 -R 17 wherein L 4 is C 1-4 alkylene chain, -O-, or -N(R a )- where R a is hydrogen or methyl, and R 17 is hydrogen or C 1-3 alkyl.
- R 5 is selected from those depicted in Table 1, below.
- X is a bond
- L 1 is -N(R 8 )C(O)-, -N(R 10 )S(O) 2 -,–C(O)-, or -S(O) 2 - (e.g., L 1 is -N(R 8 )C(O)-, -N(R 10 )S(O) 2 -, or -S(O) 2 -);
- R 2 is hydrogen, methyl, ethyl, or cyclopropylmethyl;
- L 2 is a bond,–C(O)- or - C(O)-O-;
- R 3 is C 1-3 alkyl, cyclopropyl, or 6-membered heteroaryl (e.g., R 3 is C 1-3 alkyl), each of which being optionally substituted with 1-2 R 6 ;
- R 4 is fluoro, chloro, C 1-3 alkyl, trifluoromethyl, hydroxyl, methoxy,–NH 2 or–NH-C 1-3 aliphatic (e.g., R 4 is fluoro, chloro, C 1-3 alkyl, trifluoromethyl, hydroxyl,–NH 2 or–NH-C 1-3 alkyl);
- n 0-2 (e.g., m is 1 or 2);
- R 4 is substituted at the ring carbon between the ring nitrogen and the ring carbon to which–L 1 -R 1 is substituted;
- n 0 or 1
- m is 1 and substituted at the ring carbon between the ring nitrogen and the ring carbon to which–L 1 -R 1 is substtute . In some embodiments m is 2 and one R 4 is substituted at the ring carbon betwe whereas the other R 4 is substituted
- L 1 is -N(R 8 )C(O)- or -N(R 10 )S(O) 2 - where each of R 8 and R 10 , independently, optionally join with R 4 to form an optionally substituted 5-7-membered heterocyclyl.
- L 1 is -N(R 8 )C(O)- or -N(R 10 )S(O) 2 - where each of R 8 and R 10 , independently, is hydrogen, methyl, or ethyl;
- R 1 is C 1-4 alkyl, phenyl, naphthyl 3-6-membered cycloaliphatic, 3-6-membered heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- R 3 is C 1-3 alkyl; and
- R 4 is halo or–L 4 -R 17 wherein L 4 is C 1-4 alkylene chain, - O-, or -N(R z )- where R z is hydrogen or methyl, and R 17 is hydrogen or C 1-3 alkyl.
- R 4 is methyl, ethyl, fluoro, chloro, -NH
- L 1 is–C(O)- and R 1 is , , , or .
- the compound of formula I has a structure according to any of formulas I-A to I own below:
- the compound of formula I has a structure according to formula II,
- R 3 , R 4 , and m are as defined herein, wherein (m-1) ⁇ 0.
- (m-1) is
- (m-1) i is 0, the pyridyl moiety comprises only the one R 4 group shown as shown in Formula II-a;.
- (m-1) is 1. That is, there are two R 4 and a first one is substituted at the ring carbon between the ring nitrogen and the ring carbon to which–L 1 -R 1 is substituted whereas the other R 4 is substituted either at the para or ortho position with respect to the ring nitrogen as shown in Formulas II-b and II-c
- the R 4 substituted at the para position with respect to the ring nitrogen is methyl.
- L 1 is -N(R 10 )S(O) 2 -.
- the compound of formula I has a structure according to any of formulas III, IV, IV’, V, VI, and VI’:
- each R 4 is independently -NH 2 , halo (e.g., F or Cl), optionally substituted C 1-3 alkyl, or -O-(optionally substituted C 1-3 alkyl).
- each R 6 is independently halo (e.g., F or Cl), optionally substituted C 1-3 alkyl, or -O-(optionally substituted C 1-3 alkyl).
- both R 6 are Cl.
- both R 6 are F.
- one R 6 is F and the other R 6 is Cl.
- R 3 is optionally substituted C 1-3 alkyl.
- the compound of formula I has a structure according to formula VII,
- R 1 and R 16 are each optio alkyl.
- the compound of formula I has a structure according to formula VIII,
- L 1 is -C(O)- and R 1 is where p is 1-4.
- R 1 can be substituted with 1-2 R 6 where R 6 is C 1-4 alkyl (e.g., methyl) or halo (e.g., fluoro).
- R 4 is halo or–L 4 -R 17 wherein L 4 is C 1-4 alkylene, -O-, or -N(R z )- where R z is hydrogen or methyl, and R 17 is hydrogen or C 1-3 aliphatic.
- R 4 is methyl, ethyl, fluoro, chloro, -NH 2 , methoxy, or ethoxy.
- R 6 is cyano, fluoro, chloro, C 1-6 alkyl (e.g., methyl), 3-6- membered cycloalkyl, or phenyl.
- (m-1) is 0. That is, there is only one R 4 and it is substituted at the ring carbon between the ring nitrogen and the ring carbon to which–L 1 -R 1 is substituted as shown in Formula VIII-A,
- (m-1) is wo R 4 and a first one is substituted at the ring carbon between the ring nitrogen and the ring carbon to which–L 1 -R 1 is substituted whereas a second R 4 is substituted either at the para (see Formula VIII-B) or ortho position (see Formula VIII-C) with respect to the ring nitrogen,
- the second R 4 is substituted at the para position with respect to the ring nitrogen. In some embodiments, the second R 4 is methyl.
- the compound of formula I has a structure according to any of formulas VIII-D to VIII-O
- the present invention also provides compounds of formulas A and B:
- V and W are as defined herein and one of V and W is a halide group (e.g., bromo) or pseudohalide group (e.g., cyanide) and the other is a boronic acid or a derivative.
- V can be bromo or iodo and W can be–B(OR a )(OR b ) where each of R a and R b is independently hydrogen or C 1-3 alkyl, and R a and R b can join together to form an optionally substituted 5-6 membered heterocyclyl (together with B and O).
- the invention provides a composition comprising a compound according to formula A and a compound according to formula B.
- the present invention also provides a method of coupling a compound of formula A to a compound of formula B to form a compound of formula I.
- the method comprises reacting a compound of formula A with a compound of formula B in the presence of a palladium catalyst (e.g., Pd(PPh 3 ) 3 , Pd(dppf)Cl 2 , or Pd 2 (dba) 3 ) and a base (potassium carbonate or sodium carbonate) in an appropriate solvent (e.g., dioxane or THF).
- a palladium catalyst e.g., Pd(PPh 3 ) 3 , Pd(dppf)Cl 2 , or Pd 2 (dba) 3
- a base potassium carbonate or sodium carbonate
- the present invention provides a compound depicted in Table 1, above, or a pharmaceutically acceptable salt thereof.
- the compound is I-30, I-32, I-41, I-94, I-153, I-214, I-218, I-225, I-237, I-246, I-291, I-292, I-293, I-294, I-296, I-299, I-304 or I-308 or a pharmaceutically acceptable salt thereof.
- the compound is I-41, I-94, I-153, I- 299, or I-308 or a pharmaceutically acceptable salt thereof.
- the compounds of the present invention can be prepared by methods known to one of ordinary skill in the art and / or by reference to the schemes shown below and the synthetic examples that follow. Exemplary synthetic routes are set forth in the Schemes below, and in the Examples. The person skilled in the art will understand that the synthetic schemes presented herein can be adapted for the preparation of regioisomeric compounds (e.g., compounds where, for example an R 4 group is located at a different position on the ring than that depicted in the exemplary schemes) or compounds comprising a different number of substituent groups (e.g., additional R 4 groups).
- regioisomeric compounds e.g., compounds where, for example an R 4 group is located at a different position on the ring than that depicted in the exemplary schemes
- substituent groups e.g., additional R 4 groups
- I-A, I-B, or I- C e.g., com ridine-3- sulfonyl chloride ii (e.g., 2-amino-5-bromopyridine-3-sulfonyl chloride). See Banka et al., Intl. App. Pub. No. WO 2012/037108. Treatment of ii with an amine in the presence of an appropriate base provides access to sulfonamide containing material iii where R 1 is a variously substituted nitrogen (Method A).
- treatment of ii with hydrazine followed by base and an alkyl or benzyl halide provides variously substituted sulfones of iii (Method B).
- treatment of ii with aqueous acid can provide the sulfonic acid (Method C).
- the resulting sulfonamides or sulfones can undergo Suzuki coupling with a suitable boron reagent (Method D) using, for example, Pd(dppf)Cl 2 , Pd(amphos)Cl 2 , XPhosG3/XPhos (see Buchwald, S.L. et. Al, Chem.
- Stille coupling with an organotin species using conditions such asPd(PPh 3 ) 4 , CuI and LiCl in a suitable solvent such as dioxane can also be used to generate compounds I-A, I-B, or I-C (for a review of the Stille reaction, see W.J. Scott et al.,“The Stille Reaction” Organic Reations, 2004, Wiley: Online).
- Method E a suitable solvent such as dioxane
- compounds similar to I-A, I-B, or I-C wherein R 4 is substituted at a different position on the pyridine ring can be prepared using the reaction as shown in Scheme 1.
- Scheme 2 General method for the preparation of substituted bipyridyls I-D
- pounds of formula I-D starting from 2-subst yridines e.g., 2-substituted-4- chloropyridines or 2-substituted-4-iodopyridines
- Scheme 3 shows a general route for the preparation of compounds of formula I-E starting from variously substituted 3-amino-pyridines vi.
- These intermediates can be coupled with the appropriately substituted boron reagent (Method D) or organotin species (Method E) to afford compounds of formula I-E.
- Scheme 4 shows a general route for the preparation of compounds of formula I-F and I-G starting from variously substituted pyridines with a carboxylic acid moiety at the 3-position.
- Treatment of viii with an amine ix and an appropriate coupling reagent such as TBTU in an appropriate solvent such as DCM affords amides of the formula x.
- These intermediates can be coupled with the appropriately substituted boron reagent (Method D) or organotin species (Method E) to afford compounds of formula I- F.
- These intermediates can be coupled with the appropriately substituted boron reagent (Method D) or organotin species (Method E) to afford compounds of formula I-F.
- intermediate x is a Weinreb amide (for an example of Weinreb amide preparation, see: Sun, X. et. al. Intl. App. Pub. No.
- Scheme 5 shows a general route for the preparation of compounds I-H from starting materials xiii. Reaction with sulfonyl halides (Method J) or alkyl halides (Method K) under basic conditions in an appropriate solvent such as THF or DCM can provide compounds xiv. Further treatment with the appropriately substituted boron reagent (Method D) or organotin species (Method E) affords compounds of formula I-H.
- Scheme 6 ridyls I-I
- Scheme 6 shows a general route for the preparation of compounds I-I from starting materials vi (see, e.g., Scheme 3). Treatment of compounds vi with the appropriately substituted boron reagent (Method D) or organotin species (Method E) affords compounds of formula xv. Further treatment using Method J leads to the final compounds I-I.
- Scheme 7 General method for the preparation of substituted bipyridyls I-J
- Scheme 7 shows a general route for the preparation of substituted bipyridyls I-J from starting materials xvi.
- Treatment of xvi with an oxidant such as mCPBA leads to the intermediates xvii.
- Further treatment with the appropriately substituted boron reagent (Method D) or organotin species (Method E) affords compounds of formula I-J.
- Scheme 8 General method for the preparation of substituted bipyridyls I-K
- Scheme 8 shows a general route for the preparation of compounds I-K from starting material xviii.
- Reaction of the amine in the 3-position in xviii with cyclopropanecarboxaldehyde xix under acidic conditions in a suitable solvent such as DCM provides the intermediate imine, which can then be reduced with an appropriate reagent such as NaBH(OAc) 3 in a suitable solvent such as DCM to provide intermediate xx.
- Intermdiate xxi can be generated from xx by treatment with the appropriately substituted boron reagent (Method D) or organotin species (Method E).
- Compounds xxi can be further transformed by reaction with sulfamide under basic conditions to provide compounds of formula I-K.
- Scheme 9 General method for the preparation of substituted bipyridyls I-L
- Compound xxv can be treated under Method J to provide the sulfonamides xxvi, which can undergo further treatment with the appropriately substituted boron reagent (Method D) or organotin species (Method E) to afford compounds of formula I-M.
- Scheme 11 dines I-N [00129]
- Scheme 11 shows a general route for the preparation of compounds I-N from starting material xxvii.
- Compound xxvii can be treated with chlorosulfonic acid to provide the sulfonyl chloride xxviii.
- Treatment of xxviii with disubstituted amines in a suitable solvent such as DCM provides intermediates xxx.
- Scheme 14 General method of the preparation of substituted 1H-pyrrolo[2,3-b]pyridines I-Q
- starting materials xx conditions such as sodium h s xxxvii, which can be further transformed by oxidation with mCPBA in a suitable solvent such as DMF to provide intermediates xxxviii.
- Compounds xxxviii can be further transformed by treatment with the appropriately substituted boron reagent (Method D) or organotin species (Method E) to afford compounds of formula I- Q.
- Scheme 15 General method of the preparation of substituted 1H-pyrazolo[3,4-b]pyridines I-R
- Scheme 15 shows a general route for the preparation of compounds I-R from starting material xxxix.
- Compound xxxix can be transformed by treatment with the appropriately substituted boron reagent (Method D) or organotin species (Method E) to afford intermediates xl.
- the acyl group of compounds xl can be removed under basic conditions in an appropriate solvent such as methanol to provide intermediates xli.
- This intermediate can be further transformed by reaction with an acyl or alkyl halide under basic conditions in an appropriate solvent such as THF or DCM to provide compounds of the formula I-R.
- Scheme 16 General method of the preparation of substituted 1H-pyrrolo[2,3-b]pyridines I-S [00134] starting materials xlii such as butanol, followed by ediates xliv. Compounds xliv can undergo treatment with the appropriately substituted boron reagent (Method D) or organotin species (Method E) affords compounds of formula I-S.
- Scheme 17 General method for the preparation of substituted bipyridyls I-T
- Scheme 17 shows a general route for the preparation of compounds of formula I-T starting from 2-substituted 4-bromo-pyridines xlvii.
- Treatment of compound xlvii with tin chloride provides compound xlviii, which reacts with trimethoxymethane to provide compounds xlix.
- the coupling of compound xlix with the appropriately substituted boron reagent (Method D) or organotin species (Method E) affords compounds of formula I-T.
- Scheme 18 yridyls I-U
- Scheme 18 shows a general route for the preparation of compounds of formula I-U using starting materials I, where X’ and X” can be various groups.
- Scheme 19 shows a general route for the preparation of compounds of formula I-V starting from variously substituted 3-amino-pyridines lii.
- a suitable base such as pyridine or LiHMDS
- a base such as an alkyl halide, acyl halide or sulfonyl chloride
- These intermediates can be coupled with the appropriately substituted boron reagent (Method D) or organotin species (Method E) to afford compounds of formula I-W.
- Scheme 21 shows a general route for the preparation of compounds of formula I-X and I-Y starting from variously substituted pyridines lvi with a carboxylic acid moiety at the 3-position.
- halides of formula lvii can be converted to boronic esters and/or boronic acids lviii by reaction with bis(pinacolato)diboron in the presence of a catalyst such as Pd(dppf)Cl 2 and a base such as KOAc.
- the intermediates lviii can be coupled with the appropriately substituted halogen reagent (Method D) to afford compounds of formula I-X.
- intermediate lvii is a Weinreb amide (for an example of Weinreb amide preparation, see: Sun, X. et. al. Intl. App. Pub. No. WO 2012/009227 A1 ), treatment with an appropriately substituted Grignard reagent in a solvent such as THF generates compounds of the formula lix which can be coupled with the appropriately substituted boron reagent (Method D) or organotin species (Method E) to afford compounds of formula I-Y.
- a solvent such as THF
- the present invention provides compounds that can be useful as inhibitors of VPS34, and thus the present compounds can be useful for treating proliferative, inflammatory, cardiovascular, or proliferative disorders (such as tumor and/or cancerous cell growth) mediated by VPS34.
- the compounds can be useful in the treatment of cancers in a subject, including, but not limited to, lung and bronchus, including non-small cell lung cancer (NSCLC), squamous lung cancer, brochioloalveolar carcinoma (BAC), adenocarcinoma of the lung, and small cell lung cancer (SCLC); prostate, including androgen-dependent and androgen-independent prostate cancer; breast, including metastatic breast cancer; pancreas; colon and rectum; thyroid; liver and intrahepatic bile duct; hepatocellular; gastric; endometrial; melanoma; kidney; and renal pelvis, urinary bladder; uterine corpus; uterine cervix; ovary, including progressive epithelial or primary peritoneal cancer; multiple myeloma; esophagus; acute myelogenous leukemia (AML); chronic myelogenous leukemia (CML), including accelerated CML and CML blast phase (CML-BP);
- neuroendocrine including metastatic neuroendocrine tumors; head and neck, including , e.g., squamous cell carcinoma of the head and neck, and nasopharyngeal cancer; oral cavity; and pharynx; small intestine; bone; soft tissue sarcoma; and villous colon adenoma.
- compounds of the invention can be suitable for the treatment of breast cancer, bladder cancer, colon cancer, glioma, glioblastoma, lung cancer, hepatocellular cancer, gastric cancer, melanoma, squamous cell carcinoma, head and neck cancer, thyroid cancer, endometrial cancer, renal cancer, cervical cancer, pancreatic cancer, esophageal cancer, prostate cancer, brain cancer, or ovarian cancer.
- compounds of the invention can be suitable for the treatment of inflammatory and cardiovascular disorders including, but not limited to, allergies/anaphylaxis, acute and chronic inflammation, rheumatoid arthritis; autoimmunity disorders, thrombosis, hypertension, cardiac hypertrophy, and heart failure.
- compositions comprising any of the compounds as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle.
- these compositions optionally further comprise one or more additional therapeutic agents.
- a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable prodrugs, salts, esters, salts of such esters, or any other adduct or derivative which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.
- the present invention can also include the corresponding N-oxide of the compounds of formula I.
- the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
- A“pharmaceutically acceptable salt” means any non-toxic salt or salt of an ester of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.
- the term “inhibitorily active metabolite or residue thereof” means that a metabolite or residue thereof is also an inhibitor of VPS34.
- compositions of this invention include those derived from suitable inorganic and organic acids and bases.
- Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
- inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
- organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
- salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
- Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4 salts.
- This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersable products may be obtained by such quaternization.
- Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
- the pharmaceutically acceptable compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
- a pharmaceutically acceptable carrier, adjuvant, or vehicle which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
- Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions
- any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention.
- materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc
- a method for treating a proliferative, inflammatory, or cardiovascular disorder comprising administering an effective amount of a compound of formula I, or a pharmaceutical composition containing the same to a subject in need thereof.
- an "effective amount" of the compound of formula I or pharmaceutical composition containing the same is that amount effective for treating a proliferative, inflammatory, or cardiovascular disorder, or is that amount effective for treating cancer.
- an“effective amount” of a compound of formula I is an amount which inhibits enzymatic activity of VPS34 and thereby blocks the resulting signaling cascades that lead to the abnormal activity of members of such cascades (e.g., growth factors, receptor tyrosine kinases, protein serine/threonine kinases, G protein coupled receptors, transmembrane receptors and phospholipid kinases and phosphatases). Still in other embodiments, an “effective amount” of a compound of formula I is an amount which inhibits enzymatic activity of VPS34 and thereby leads to abnormal activity of degradation pathways mediated by the proteasome or lysosome.
- members of such cascades e.g., growth factors, receptor tyrosine kinases, protein serine/threonine kinases, G protein coupled receptors, transmembrane receptors and phospholipid kinases and phosphatases.
- the compounds and compositions, according to the method of the present invention may be administered using any amount and any route of administration effective for treating the disease.
- the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disorder, the particular agent, its mode of administration, and the like.
- the compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
- dosage unit form refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
- the specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disease being treated and the severity of the disease; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
- patient means an animal, preferably a mammal, and most preferably a human.
- compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.
- the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 200 mg/kg (e.g., from about 0.1 mg/kg to about 50 mg/kg or from about 1 mg/kg to about 25 mg/kg), of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
- Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- the oral compositions can also include adj
- Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil can be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid are used in the preparation of injectables.
- the injectable formulations can be sterilized, for example, by filtration through a bacterial- retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
- a compound of the present invention In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide.
- the rate of compound release can be controlled.
- biodegradable polymers include poly(orthoesters) and poly(anhydrides).
- Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
- compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar--agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
- Compounds of this invention can also be in micro-encapsulated form with one or more excipients as noted above.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
- the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
- Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
- the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
- buffering agents include polymeric substances and waxes.
- Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
- the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
- Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention.
- the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body.
- Such dosage forms can be made by dissolving or dispensing the compound in the proper medium.
- Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
- one or more of the compounds of this invention may be used in an application of monotherapy to treat a disorder, disease or symptom, they also may be used in combination therapy, in which the use of an inventive compound or composition (therapeutic agent) is combined with the use of one or more other therapeutic agents for treating the same and/or other types of disorders, symptoms and diseases.
- Combination therapy includes administration of the therapeutic agents concurrently or sequentially.
- the therapeutic agents can be combined into one composition which is administered to the patient.
- the compounds of this invention are used in combination with other therapeutic agents.
- the additional therapeutic agent is selected from other inhibitors of VPS34.
- a compound of the invention is administered in conjunction with a therapeutic agent selected from the group consisting of cytotoxic agents, radiotherapy, and immunotherapy. It is understood that other combinations may be undertaken while remaining within the scope of the invention.
- any compound of this invention or pharmaceutically acceptable salt described herein can be administered in conjunction with a second therapeutic agent (e.g., an autophagy inducer, an EGFR inhibitor, a tyrosine kinase inhibitor (TKI), a receptor tyrosine kinase inhibitor (RTKI), or a PI3K pathway inhibitor such as an mTOR inhibitor).
- a second therapeutic agent e.g., an autophagy inducer, an EGFR inhibitor, a tyrosine kinase inhibitor (TKI), a receptor tyrosine kinase inhibitor (RTKI), or a PI3K pathway inhibitor such as an mTOR inhibitor.
- TKI tyrosine kinase inhibitor
- RTKI receptor tyrosine kinase inhibitor
- PI3K pathway inhibitor such as an mTOR inhibitor
- the therapeutic agent is gefitinib (Iressa TM ), erlotinib (Tarceva ® ), cetuximab (Erbitux ® ), afatinib (Gilotrif TM ), lapatinib (Tykerb ® ), panitumumab (Vectibix ® ), vandetanib (Caprelsa ® ), CO-1686 (N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoro methyl)pyrimidin-4-yl)amino)phenyl)acrylamide; Clovis Oncology), AZD9291 (AstraZeneca), axitinib (Inlyta ® ), dasatinib (Sprycel ® ), imatinib (Gleevec ® ), nilotin
- the additional therapeutic agent for use in combination therapy is erlotinib, afatinib, lapatinib, or CO-1686.
- the additional therapeutic agent is selected from gefitinib, vandetanib, and panitumumab.
- the additional therapeutic agent is cetuximab.
- Combination therapy can be administered with any of the compounds of the invention described herein, or a pharmaceutically acceptable salt thereof.
- the compound is selected from the compounds of Table 1, or pharmaceutically acceptable salts thereof.
- the compound is I-30, or a pharmaceutically acceptable salt thereof.
- the compound is I-32, or a pharmaceutically acceptable salt thereof.
- the compound is I-41, or a pharmaceutically acceptable salt thereof.
- the compound is I-94, or a pharmaceutically acceptable salt thereof.
- the compound is I-153, or a pharmaceutically acceptable salt thereof.
- the compound is I-214, or a pharmaceutically acceptable salt thereof.
- the compound is I-299, or a pharmaceutically acceptable salt thereof.
- the compound is I-308, or a pharmaceutically acceptable salt thereof.
- the additional agents may be administered separately from a provided combination therapy, as part of a multiple dosage regimen.
- those agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as part of a combination therapy, the two therapeutic agents may be submitted simultaneously, sequentially or intermittently.
- Combination therapy can be used for any of the therapeutic indications described herein.
- the combination therapy is for the treatment of a proliferative disorder (e.g., cancer) in a patient.
- a proliferative disorder e.g., cancer
- the proliferative disorder is breast cancer, bladder cancer, colon cancer, glioma, glioblastoma, lung cancer, hepatocellular cancer, gastric cancer, melanoma, squamous cell carcinoma, head and neck cancer, thyroid cancer, endometrial cancer, renal cancer, cervical cancer, pancreatic cancer, esophageal cancer, prostate cancer, brain cancer, or ovarian cancer.
- the proliferative disorder is breast cancer, pancreatic cancer, head and neck cancer, non- small-cell lung carcinoma (NSCLC), colon cancer, renal cell carcinoma, squamous cell carcinoma, or thyroid cancer.
- the proliferative disorder is breast cancer, pancreatic cancer, head and neck cancer, non-small-cell lung carcinoma (NSCLC), or colon cancer.
- the term“combination,”“combined,” and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention.
- a combination of the present invention may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form.
- Another aspect of the invention relates to inhibiting VPS34 activity in a biological sample or a patient, which method comprises administering to the patient, or contacting said biological sample with a compound as described herein, or a composition comprising said compound.
- biological sample generally includes in vivo, in vitro, and ex vivo materials, and also includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
- Still another aspect of this invention is to provide a kit comprising separate containers in a single package, wherein the inventive pharmaceutical compounds, compositions and/or salts thereof are used in combination with pharmaceutically acceptable carriers to treat disorders, symptoms and diseases where VPS34 kinase plays a role.
- LCMS spectra were recorded on a Hewlett-Packard HP1100 or Agilent 1100 Series LC system connected to a Micromass mass spectromteter using reverse phase C18 columns. Various gradients and run times were selected in order to best characterize the compounds. Mobile phases were based on ACN/water gradients and contained either 0.1% formic acid (methods indicated as FA) or 10 mM ammonium acetate (methods indicated as AA).
- LCMS spectra were recorded on an Agilent 1290 Infinity UPLC system connected to an Agilent 6130 mass spectrometer, a Waters Acquity UPLC system connected to a Waters Acquity SQ mass spectrometer, or an Agilent 1100 Series HPLC system connected to a Waters Micromass ZQ mass spectrometer using reverse phase C18 columns.
- Various gradients and run times were selected in order to best characterize the compounds.
- Mobile phases were based on ACN/water gradients and contained either 0.1% formic acid (methods indicated as FA) or 10 mM ammonium acetate (methods indicated as AA).
- Preparative HPLC are conducted using 18x150 mm Sunfire C-18 columns eluting with water- MeCN gradients using a Gilson instrument operated by 322 pumps with the UV/visible 155 detector triggered fraction collection set to between 200 nm and 400 nm. Mass gated fraction collection is conducted on an Agilent 1100 LC/MSD instrument.
- Preparative SFC is conducted using 10, 20 or 30mm x 250mm ChiralPak columns (typically IA, IB, IC, ID, IE and IF) eluting with appropriate percentages of supercritical carbon dioxide and alcohol containing 0.3% diethyl amine or 0.3% triethylamine or 0.3% formic acid or without any acid or base additives.
- Isocratic conditions with flow rates in the range of 10-100 mL/min and a column temperature of 40 o C are typical.
- a Jasco SFC prep purification system with UV/visible triggered fraction collection set to between 200 nm and 400 nm and back pressure regulation set to 10 MPa.
- XRPD is performed using a Bruker AXS D8 Advance X-ray Diffractometer using CuKa radiation (40 kV, 40 mA), ⁇ - 2 ⁇ goniometer, and divergence of V4 and receiving slits, a Ge monochormator and a Lynxeye detector.
- Samples are run under ambient conditions as flat plate specimens using powder. The sample is gently packed into a cavity cut into polished, zero-background (510) silicon wafer. The sample is rotated in its own plane during analysis. The data are collected on an angular range of 2 to 42 °2 ⁇ , with a step size of 0.05 °2 ⁇ and a collection time of 0.5 s/step.
- N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]acetamide (6.1 g, 29%) as a white solid.
- 1 H NMR (400 MHz, DMSO-d 6 ): ⁇ 1.29 (s, 12H), 2.09 (s, 3H), 7.24 (dd, J 6.0, 1.2 Hz, 1H), 8.30-8.33 (m, 2H), 10.47 (br s, 1H).
- Step 2 N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]cyclopropanecarboxamide
- Step 2 (rac)-2,2-difluoro-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl) cyclopropanecarboxamide
- Step 1 ethyl 2-[(4-bromopyridin-2-yl)amino]-1,3-oxazole-5-carboxylate
- Step 4 N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)oxazol-2-amine
- Step 2 2-methyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-4-amine
- reaction mixture was allowed to cool to rt then the mixture was filtered through celite. The filtrate was concentrated under vacuum. The residue was washed with MTBE (300 mL) and filtered. The solid residue was added to a mixture of MTBE (2500 mL) and EtOAc (500 mL), stirred for 1 h, then filtered through celite.
- Step 2 N,N-dimethyl-N'-[2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3- yl]sulfuric diamide
- N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]acetamide (0.127 g, 0.483 mmol)
- 2-amino-5-bromo-N,N-dimethylpyridine-3-sulfonamide (0.176 g, 0.628 mmol)
- potassium carbonate 134 mg, 0.966 mmol
- 1,4-dioxane:water (4.26 mL, 6:1 mixture) and Pd(dppf)Cl 2 (19.9 mg, 0.024 mmol) were combined in a reaction vial, flushed with nitrogen and sealed.
- Step 2 the reaction mixture was heated in the microwave (120 o C, 35 min).
- step 2 was prepared from 5-bromo-2-chloro-N-phenylpyridine-3-sulfonamide according to the procedure in WO2012/037108, p.268.
- Step 3 N-[6-amino-5-(methylsulfonyl)-3,4'-bipyridin-2'-yl]acetamide
- Step 3 N-[6-amino-5-(methylsulfonyl)-3,4'-bipyridin-2'-yl]acetamide (5.0 mg, 1.5%).
- LCMS (FA): m/z 307.2 (M+H).
- Step 2 2'-acetamido-6-amino-3,4'-bipyridine-5-sulfonic acid
- Step 3 N- ⁇ 5-[(cyclopropylsulfonyl)(methyl)amino]-6-methyl-3,4'-bipyridin-2'-yl ⁇ acetamide
- Step 2 N-(5- ⁇ [(2,4-difluorophenyl)sulfonyl]amino ⁇ -6-methyl-3,4'-bipyridin-2'-yl)acetamide
- N-(5-bromopyridin-3-yl)-3-chloropropane-1-sulfonamide (0.29 g, 0.79 mmol)
- N-[4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]acetamide (0.27 g, 1.03 mmol)
- [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium (65 mg, 0.079 mmol) and cesium carbonate (0.77 g, 2.37 mmol) were taken up in 1,4-dioxane (2.16 mL) and water (0.37 mL) under an atmosphere of nitrogen.
- Step 2 conditions use Pd(PPh 3 ) 4 , 1.0 M Na 2 CO 3; toluene, EtOH, microwave irradiation t t Step 2 conditions use XPhosG3; 0.500 M of K 3 PO 4 , dioxane, microwave irradiation at130 o C ⁇ Step 2 conditions use Pd 2 (dba) 3,, XPhos, KOAC, dioxane, water,110 o C
- Step 2 conditions use K 2 CO 3 instead of Cs 2 CO 3 and microwave irradiation ranging from 120- 150 o C
- Step 2 conditions use SiliaCat DPP-Pd instead of Pd(dppf)Cl 2 and microwave irradiation ***Chiral Separation conditions
- Step 2 methyl 4-amino-6-bromopyrazolo[1,5-a]pyridine-3-carboxylate
- Step 1 N-( -2- yl)oxy)ethyl
- Step 2 N-(bicyclo[1.1.1]pentan-1-yl)-5-bromo-2-chloro-N-(2-hydroxyethyl)pyridine-3-sulfonamide
- Step 3 2-(bicyclo[1.1.1]pentan-1-yl)-8-bromo-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepine 1,1-dioxide
- Example 9DC N-(5-(8-fluoro-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl)-[3,4'- bipyridin]-2'-yl)acetamide (I-405)
- Step 2 N-(5- ⁇ [(2-chloro-4-fluorophenyl)sulfonyl]amino ⁇ -6-methyl-3,4'-bipyridin-2'- yl)acetamide
- N-(5-amino-6-methyl-3,4'-bipyridin-2'-yl)acetamide 125 mg, 0.52 mmol
- 2-chloro-4- fluorobenzenesulfonyl chloride (0.09 mL, 0.62 mmol) were suspended in pyridine (1.25 mL) and heated at 110 °C overnight. The reaction was cooled and concentrated. The crude compound was purified by column chromatography to provide N-(5- ⁇ [(2-chloro-4-fluorophenyl)sulfonyl]amino ⁇ -6-methyl-3,4'- bipyridin-2'-yl)acetamide (107 mg, 48%).
- LCMS (FA): m/z 435.1 (M+H).
- Step 2 methyl iodide was used as the electrophile, NaH as the base, and DMF as the solvent.
- Step 3 two equivalents of 2M 1M K 2 CO 3 was used instead of 1.4 equivalents of 1M K 2 CO 3 .
- Step 1 Et3N was used as the base.
- step 2 K 2 CO 3 was used as the base, and MeOH as the solvent.
- Step 2 K 2 CO 3 was used as the base, and ACN as the solvent.
- Step 3 coupling conditions were Pd(PPh 3 ) 4 ; LiCl; CuI; 1,4-dioxane; 120 o C.
- Step 2 K 2 CO 3 was used as the base, and ACN as the solvent.
- Step 3 conditions used Pd(PPh 3 ) 4 ; Na 2 CO 3 , EtOH/Toluene; 120 o C Synthesis of reagent (ad’) from Example 11H: 2-(5-bromo-2-methylpyridin-3-yl)-6-methyl-1,2,6- thiadiazinane 1,1-dioxide
- Step 2 N- ⁇ 6-(methylamino)-5-[methyl(methylsulfonyl)amino]-3,4'-bipyridin-2'-yl ⁇ acetamide
- Step 2 methyl (5- ⁇ [(2,4-difluorophenyl)sulfonyl]amino ⁇ -6-methyl-3,4'-bipyridin- 2'-yl)carbamate
- Step 1 5-bromo-N2-(cyclopropylmethyl)pyridine-2,3-diamine; 5-bromo-N,N'- bis(cyclopropylmethyl)pyridine-2,3-diamine; 5-bromo-N3-(cyclopropylmethyl)pyridine-2,3-diamine
- Step 1 (2E)-3-(5-bromopyridin-3-yl)-1-(4-fluorophenyl)prop-2-en-1-one
- Step 2 N- ⁇ 5-[(1E)-3-(4-fluorophenyl)-3-oxoprop-1-en-1-yl]-3,4'-bipyridin-2'-yl ⁇ acetamide
- a microwave tube was charged with N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)pyridin-2-yl]acetamide (153 mg, 0.582 mmol), 2-amino-5-bromo-N,N-dimethylnicotinamide (115 mg, 0.471 mmol) and Pd(dppf)Cl 2 (24 mg, 0.030 mmol). 1,4-dioxane (3.7 mL, 47 mmol) and potassium carbonate (2 M in water; 0.471 mL, 0.942 mmol) were added. The tube was purged with nitrogen and heated at 130 °C for 30 min in the microwave.
- Step 1 HATU, DIEA, and DMF were used with microwave irradiation (120 o C) ⁇ Step 2 conditions use Pd(PPh 3 ) 4 , 1.0 M Na 2 CO 3; toluene, and EtOH under microwave irradiation ⁇ Synthesis of reagent bl’ shown in Table 20a.
- Example 20AF 6-Amino-N-carbamimidoyl-2'-(pyrimidin-4-ylamino)-3,4'-bipyridine-5- carboxamide I-216
- Step 2 XPhosG3 was used with K 3 PO 4 in 1,4-dioxane; microwave irradiation (130 o C) ⁇ Step 2 conditions use Pd(PPh 3 ) 4 , 1.0 M Na 2 CO 3; toluene, and EtOH under microwave irradiation ⁇ ⁇ Step 1 conditions use pyridine instead of DIEA
- Step 1 5-bromo- - met y am no n cot n c ac
- Example 22B 2'-Acetamido-N-(bicyclo[1.1.1]pent-1-yl)-6-(dimethylamino)- 3,4'-bipyridine-5- carboxamide (I-283)
- Step 1 N-(Bicyclo[1.1.1]pent-1-yl)-5-bromo-2-(dimethylamino)nicotinamide
- Step 2 2'-Acetamido-N-(bicyclo[1.1.1]pent-1-yl)-6-(dimethylamino)- 3,4'-bipyridine-5- carboxamide
- Example 22C N-(bicyclo[1.1.1]pent-1-yl)-6-(dimethylamino)-N-methyl-2'-((2-methylpyrimidin-4- yl)amino)- 3,4'-bipyridine-5-carboxamide (I-306)
- N-(bicyclo[1.1.1]pent-1-yl)-5-bromo-2-fluoronicotinamide 500 mg, 1.75 mmol was dissolved in THF (15 mL). The reaction mixture was cooled to 0 o C and sodium hydride (60% dispersion in mineral oil, 175 mg, 4.38 mmol) was added. To the reaction mixture, a solution of methyl iodide (0.33 mL, 5.27 mmol) in THF (0.1 mL) was added slowly. The reaction mixture was allowed to stir for 4 h. The reaction mixture was concentrated under reduced pressure and the residue was diluted with 1N HCl and extracted with Et 2 O.
- Step 4 (5-(bicyclo[1.1.1]pent-1-yl(methyl)carbamoyl)-6-(dimethylamino)pyridin-3-yl)boronic acid
- Step 5 N-(bicyclo[1.1.1]pent-1-yl)-6-(dimethylamino)-N-methyl-2'-((2-methylpyrimidin-4- yl)amino)-[3,4'-bipyridine]-5-carboxamide
- Step 5 conditions use Pd(dppf)Cl 2 and K 2 CO 3 instead of XPhosG3/XPhos and K 3 PO 4
- Step 4 the final product for example 22F is generated from direct reaction of reagent do with reagent dq using Pd(dppf)Cl 2 and K 2 CO 3 instead of XPhosG3/XPhos and K 3 PO 4
- Example 23 N- ⁇ 4-[1-(cyclopropylsulfonyl)-1H-pyrazolo[4,3-b]pyridin-6-yl]pyridin-2-yl ⁇ acetamide and N- ⁇ 4-[2-(cyclopropylsulfonyl)-2H-pyrazolo[4,3-b]pyridin-6-yl]pyridin-2-yl ⁇ acetamide I-2 and I- 105
- Step 1 6-bromo-1-(cyclopropylsulfonyl)-1H-pyrazolo[4,3-b]pyridine and 6-bromo-2- (cyclopropylsulfonyl)-2H-pyrazolo[4,3-b]pyridine
- Step 2 N- ⁇ 4-[1-(cyclopropylsulfonyl)-1H-pyrazolo[4,3-b]pyridin-6-yl]pyridin-2-yl ⁇ acetamide and N- ⁇ 4-[2-(cyclopropylsulfonyl)-2H-pyrazolo[4,3-b]pyridin-6-yl]pyridin-2-yl ⁇ acetamide
- a microwave vial was charged with N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)pyridin-2-yl]acetamide (208 mg, 0.794 mmol), Pd(dppf)Cl 2 (33 mg, 0.040 mmol) and purged with nitrogen.
- Step 2 5-bromo-N,N-dimethyl-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide
- Step 1 7-bromo-2-methyl-3,4-dihydro-2H-pyrido[2,3-e][1,2,4]thiadiazine 1,1-dioxide
- amphosdichl otassium phosphate (0.323 g, 1.52 mmol) was allowed to stir in water (0.27 mL) and DME (4.6 mL) and heated in the microwave at 150 o C for 60 min.
- the reaction mixture was partitioned between water and EtOAc and the organic layer was washed with brine.
- the aqueous layer was further extracted with a DCM/MeOH mixture.
- the combined all organic layers were dried over magnesium sulfate, filtered and concentrated by rotary evaporation. Added MeOH and filtered to remove solids and concentrated the supernatant by rotary evaporation. Purified by prep HPLC to yield N-[4-(1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-2-yl]acetamide (1.5 mg, 1.2%).
- Step 2 N- ⁇ 6-Chloro-4-methyl-2'-[(2-methylpyrimidin-4-yl)amino]-3,4'-bipyridin-5-yl ⁇ -2,4- difluorobenzenesulfonamide (I-299)
- N-(5-Bromo-2-chloro-4-methylpyridin-3-yl)-2,4-difluorobenzenesulfonamide (6.40 g, 16.1 mmol)
- 2-methyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]pyrimidin-4-amine (6.0 g, 19 mmol)
- Pd(dppf)Cl 2 (431 mg, 0.524 mmol) were combined in a round bottomed flask equipped with a stirbar.
- Step 2 conditions use SiliaCat DPP-Pd and microwave irradiation instead of Pd(dppf)Cl 2 o
- Step 5 5-bromo-2-chloro-4-ethylpyridin-3-amine
- NH 4 Cl 1942 g, 361 mmol
- Fe 20.2 g, 362 mmol
- Reagent ea is synthesized using the below procedure described for 5-bromo-3-ethoxy-2-methyl-pyridine by reacting an appropriate alkyl halide with 5-bromo-2-methyl-pyridin-3-ol
- Reagent ea is synthesized using K 2 CO 3 , DMSO, and MW irradiation at 170 C by reacting 2-fluoro-5-methyl pyridine with 5-bromo-2-methyl-pyridin-3-ol
- Reagent ea is synthesized by reacting 5-bromo-2-methyl-pyridin-3-ol , diphenyliodonium trifluoromethanesulfonate and NaOtBu in THF at 70 C
- Reagent ea is synthesized according to the procedure for reagent u from example 9BG
- Reagent ea is synthesized according to the below procedure described for intermediates of example 34AC, 34AD, 34AE, 34AF
- a 5 mL microwave tube equipped with a stir bar was charged with 5-chloropyridin-3-ol (232 mg, 1.79 mmol), N'-[(1E)-4-fluoro-2,3-dihydro-1H-inden-1-ylidene]-4-methylbenzenesulfonohydrazide (285 mg, 0.895 mmol), potassium carbonate (433 mg, 3.13 mmol), and fluorobenzene (3 ml).
- the tube was sealed and the reaction mixture was subjected to microwave irradiation at 160 °C for 1 h.
- the reaction mixture was allowed to cool to rt, then the vial was opened and the reaction mixture was poured into stirring 1N NaOH.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2015206652A AU2015206652A1 (en) | 2014-01-14 | 2015-01-13 | Heteroaryls and uses thereof |
MYPI2016702312A MY182908A (en) | 2014-01-14 | 2015-01-13 | Heteroaryls and uses thereof |
AP2016009368A AP2016009368A0 (en) | 2014-01-14 | 2015-01-13 | Heteroaryls and uses thereof |
TN2016000270A TN2016000270A1 (en) | 2014-01-14 | 2015-01-13 | Heteroaryls and uses thereof. |
SG11201604820XA SG11201604820XA (en) | 2014-01-14 | 2015-01-13 | Heteroaryls and uses thereof |
MA39204A MA39204B1 (en) | 2014-01-14 | 2015-01-13 | Heteroaryl derivatives inhibiting vps34 and / or p13 for the treatment of proliferative, inflammatory or cardiovascular disorders |
CN201580004591.2A CN105916503B (en) | 2014-01-14 | 2015-01-13 | Heteroaryl compounds and uses thereof |
KR1020167022343A KR20160122736A (en) | 2014-01-14 | 2015-01-13 | Heteroaryls and uses thereof |
CR20160363A CR20160363A (en) | 2014-01-14 | 2015-01-13 | HETEROARILOS AND USES OF THESE |
MX2016009135A MX2016009135A (en) | 2014-01-14 | 2015-01-13 | Heteroaryls and uses thereof. |
EA201691421A EA032458B1 (en) | 2014-01-14 | 2015-01-13 | Heteroaryls and use thereof |
BR112016016289-7A BR112016016289B1 (en) | 2014-01-14 | 2015-01-13 | HETEROARIS AND USES THEREOF |
CA2935867A CA2935867C (en) | 2014-01-14 | 2015-01-13 | Heteroaryls and uses thereof |
ES15737173T ES2908042T3 (en) | 2014-01-14 | 2015-01-13 | Heteroaryls and uses thereof |
EP15737173.3A EP3094325B1 (en) | 2014-01-14 | 2015-01-13 | Heteroaryls and uses thereof |
JP2016546472A JP6609258B2 (en) | 2014-01-14 | 2015-01-13 | Heteroaryls and their use |
PH12016501388A PH12016501388A1 (en) | 2014-01-14 | 2016-07-13 | Heteroaryls and uses thereof |
IL246755A IL246755A0 (en) | 2014-01-14 | 2016-07-13 | Heteroaryls and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461927055P | 2014-01-14 | 2014-01-14 | |
US61/927,055 | 2014-01-14 | ||
US201462054742P | 2014-09-24 | 2014-09-24 | |
US62/054,742 | 2014-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015108861A1 true WO2015108861A1 (en) | 2015-07-23 |
Family
ID=53543363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/011191 WO2015108861A1 (en) | 2014-01-14 | 2015-01-13 | Heteroaryls and uses thereof |
Country Status (26)
Country | Link |
---|---|
US (3) | US9802960B2 (en) |
EP (1) | EP3094325B1 (en) |
JP (1) | JP6609258B2 (en) |
KR (1) | KR20160122736A (en) |
CN (1) | CN105916503B (en) |
AP (1) | AP2016009368A0 (en) |
AU (1) | AU2015206652A1 (en) |
BR (1) | BR112016016289B1 (en) |
CA (1) | CA2935867C (en) |
CL (1) | CL2016001805A1 (en) |
CR (1) | CR20160363A (en) |
DO (1) | DOP2016000173A (en) |
EA (1) | EA032458B1 (en) |
EC (1) | ECSP16067303A (en) |
ES (1) | ES2908042T3 (en) |
GE (1) | GEP20196983B (en) |
IL (1) | IL246755A0 (en) |
MX (1) | MX2016009135A (en) |
MY (1) | MY182908A (en) |
PE (1) | PE20161313A1 (en) |
PH (1) | PH12016501388A1 (en) |
SG (1) | SG11201604820XA (en) |
TN (1) | TN2016000270A1 (en) |
TW (1) | TWI662024B (en) |
UY (1) | UY35951A (en) |
WO (1) | WO2015108861A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3012259A4 (en) * | 2013-06-19 | 2016-11-23 | Shanghai Inst Materia Medica | Five-membered heterocyclic pyridine compounds and preparation method and use thereof |
WO2017068412A1 (en) * | 2015-10-21 | 2017-04-27 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
WO2017140841A1 (en) | 2016-02-19 | 2017-08-24 | Sprint Bioscience Ab | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
WO2017140843A1 (en) | 2016-02-19 | 2017-08-24 | Sprint Bioscience Ab | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes |
US9751854B2 (en) | 2014-01-14 | 2017-09-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
WO2018193410A1 (en) * | 2017-04-20 | 2018-10-25 | Otsuka Pharmaceutical Co., Ltd. | 6-pyrimidin-isoindole derivative as erk1/2 inhibitor |
US10202373B2 (en) | 2014-01-14 | 2019-02-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
WO2019038387A1 (en) | 2017-08-23 | 2019-02-28 | Sprint Bioscience Ab | Pyridylpyridone compounds |
WO2019038390A1 (en) | 2017-08-23 | 2019-02-28 | Sprint Bioscience Ab | Morpholinylpyridone compounds |
WO2019038389A1 (en) | 2017-08-23 | 2019-02-28 | Sprint Bioscience Ab | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds |
WO2019038384A1 (en) | 2017-08-23 | 2019-02-28 | Sprint Bioscience Ab | Azaindolylpyridone and diazaindolylpyridone compounds |
WO2019052932A1 (en) | 2017-09-18 | 2019-03-21 | Basf Se | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi |
WO2020045941A1 (en) * | 2018-08-27 | 2020-03-05 | 주식회사 대웅제약 | Novel heterocyclic amine derivative and pharmaceutical composition comprising same |
CN112574207A (en) * | 2019-09-30 | 2021-03-30 | 南京药石科技股份有限公司 | ERK1/2 protein kinase inhibitor and application thereof |
RU2760184C1 (en) * | 2018-08-27 | 2021-11-22 | Даевунг Фармасьютикал Ко., Лтд. | New heterocyclic amine derivative and a pharmaceutical composition containing it |
RU2779018C1 (en) * | 2015-10-21 | 2022-08-30 | Оцука Фармасьютикал Ко., Лтд. | Benzolactams as protein kinase inhibitors |
US11801238B2 (en) | 2020-11-25 | 2023-10-31 | Deciphera Pharmaceuticals, Llc | Anti-viral activity of VPS34 inhibitors |
WO2024084363A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Use of patatin-like phospholipase domain-containing protein 3 compounds |
WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
WO2024095003A1 (en) * | 2022-11-02 | 2024-05-10 | Cerevance, Inc. | Nicotinamide derivatives for use in treating disorders associated with kcnk13 activity |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018144791A1 (en) * | 2017-02-03 | 2018-08-09 | Millennium Pharmaceuticals, Inc. | Combination of vps34 inhibitors and mtor inhibitors |
CN109608444B (en) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | Isoindolinone-containing ERK inhibitor and preparation method and application thereof |
JP2022548568A (en) * | 2019-09-11 | 2022-11-21 | プレリュード・セラピューティクス・インコーポレイテッド | CDK inhibitors and their use as pharmaceuticals |
TWI779487B (en) * | 2020-02-13 | 2022-10-01 | 大陸商勁方醫藥科技(上海)有限公司 | Dihydronaphthyridone compounds, their preparation method and medical use |
TWI824626B (en) * | 2021-08-02 | 2023-12-01 | 大陸商勁方醫藥科技(上海)有限公司 | Crystal forms of RIPK1 inhibitors and their acid salts and crystal forms of their acid salts |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110130380A1 (en) | 2009-09-04 | 2011-06-02 | Barsanti Paul A | Heteroaryl Kinase Inhibitors |
WO2012009227A1 (en) | 2010-07-16 | 2012-01-19 | N30 Pharmaceuticals, Llc | Novel dihydropyridin-2(1h)-one compounds as s-nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists |
US20130102608A1 (en) | 2010-07-05 | 2013-04-25 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Bipyridyl derivatives |
WO2014058691A1 (en) | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE454378T1 (en) | 2002-11-01 | 2010-01-15 | Vertex Pharma | COMPOUNDS ACTIVE AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES |
FR2850652B1 (en) | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | NOVEL CYCLIC UREA DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES |
SE0402735D0 (en) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
GB0425026D0 (en) * | 2004-11-12 | 2004-12-15 | Biofocus Discovery Ltd | Compounds which bind to the active site of protein kinase enzymes |
CA2585490A1 (en) | 2004-11-12 | 2006-05-18 | Galapagos Nv | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
ZA200704971B (en) * | 2004-12-16 | 2008-09-25 | Vertex Pharma | Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases |
CA2591413A1 (en) | 2004-12-16 | 2006-06-22 | Vertex Pharmaceuticals Incorporated | Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases |
US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
CN101448827A (en) | 2006-05-22 | 2009-06-03 | 阿斯利康(瑞典)有限公司 | Indole derivatives |
US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
BRPI0716239A2 (en) | 2006-08-30 | 2013-08-13 | Cellzome Ltd | triazole derivatives as kinase inhibitors |
BRPI0720057A2 (en) | 2006-12-04 | 2013-12-17 | Astrazeneca Ab | COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, PHARMACEUTICAL COMPOSITION, BACTERIAL DNA GYRASE AND / OR TOPOISOMERASE IV INHIBITION METHODS IN A HOT BLOOD ANIMAL, PRODUCING AN ANTIBANTER EFFECT OF ANTI BLOOD OF ANTI BLOOD BACTERIAL INFECTION IN A HOT BLOOD ANIMAL, AND USE OF A PHARMACEUTICALLY ACCEPTABLE COMPOUND OR SALT |
EP2094682A2 (en) | 2006-12-22 | 2009-09-02 | Novartis AG | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
UY31137A1 (en) | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF THE PI3 QUINASA |
AU2008278966B2 (en) | 2007-07-26 | 2012-02-23 | Novartis Ag | Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions |
JP5561702B2 (en) | 2007-08-02 | 2014-07-30 | アムジエン・インコーポレーテツド | PI3 kinase modulator and method of use |
WO2009039140A1 (en) | 2007-09-17 | 2009-03-26 | Smithkline Beecham Corporation | Pyridopyrimidine derivatives as pi3 kinase inhibitors |
US20100311736A1 (en) * | 2007-10-22 | 2010-12-09 | Glaxosmithkline Llc | Pyridosulfonamide derivatives as p13 kinase inhibitors |
PE20091268A1 (en) | 2007-12-19 | 2009-09-19 | Amgen Inc | HETEROCYCLIC DERIVATIVES AS PI3 KINASE INHIBITORS |
US8343966B2 (en) | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
US8309577B2 (en) | 2008-04-23 | 2012-11-13 | Bristol-Myers Squibb Company | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands |
US8415376B2 (en) | 2008-05-30 | 2013-04-09 | Amgen Inc. | Inhibitors of PI3 kinase |
US8163743B2 (en) | 2008-06-05 | 2012-04-24 | GlaxoGroupLimited | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases |
US20110178070A1 (en) | 2008-06-24 | 2011-07-21 | Takeda Pharmaceutical Company Limited | PI3K/mTOR INHIBITORS |
WO2010007100A1 (en) | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
US8536186B2 (en) | 2008-08-04 | 2013-09-17 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
AU2009314335B2 (en) | 2008-11-11 | 2013-09-12 | Eli Lilly And Company | P70 S6 kinase inhibitor and mTOR inhibitor combination therapy |
WO2010057877A1 (en) * | 2008-11-18 | 2010-05-27 | Cellzome Limited | 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors |
US8071605B2 (en) | 2008-12-12 | 2011-12-06 | Astrazeneca Ab | Piperidine compounds for use in the treatment of bacterial infections |
KR20120034666A (en) | 2009-05-22 | 2012-04-12 | 엑셀리시스, 인코포레이티드 | Benzoxazepines based p13k/mtor inthibitors against proliferative diseases |
ES2432029T3 (en) | 2009-07-15 | 2013-11-29 | Abbvie Inc. | Pyrrolopyridine Kinase Inhibitors |
JP2011033670A (en) * | 2009-07-30 | 2011-02-17 | Sony Corp | Optical finder unit and image capturing apparatus |
ES2667049T3 (en) | 2010-02-05 | 2018-05-09 | Merck Patent Gmbh | Heteroaryl- [1,8] naphthyridine derivatives |
CN103209960A (en) | 2010-07-26 | 2013-07-17 | 百时美施贵宝公司 | Sulfonamide compounds useful as CYP17 inhibitors |
CN103153300A (en) | 2010-08-11 | 2013-06-12 | 米伦纽姆医药公司 | Heteroaryls and uses thereof |
US8478700B2 (en) | 2010-08-11 | 2013-07-02 | Brightedge Technologies, Inc. | Opportunity identification and forecasting for search engine optimization |
EP2603216A4 (en) | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | Heteroaryls and uses thereof |
WO2012037108A1 (en) | 2010-09-13 | 2012-03-22 | Glaxosmithkline Llc | Aminoquinoline derivatives as antiviral agents |
WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
JP2013542967A (en) * | 2010-11-17 | 2013-11-28 | ノバルティス アーゲー | 3- (Aminoaryl) -pyridine compound |
CN103270026A (en) | 2010-12-21 | 2013-08-28 | 诺瓦提斯公司 | Bi-heteroaryl compounds as vps34 inhibitors |
US8815853B2 (en) | 2010-12-23 | 2014-08-26 | Sanofi | Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof |
AR085013A1 (en) * | 2011-01-26 | 2013-08-07 | Sanofi Aventis | SUBSTITUTED 3-HETEROAROILAMINE-PROPIONIC ACID DERIVATIVES AND ITS USE AS PHARMACEUTICAL SUBSTANCES |
CN103339110A (en) | 2011-01-28 | 2013-10-02 | 诺瓦提斯公司 | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
WO2012101064A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
WO2012101066A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Pyridine biaryl amine compounds and their uses |
DE102011077104A1 (en) | 2011-06-07 | 2012-12-13 | Siemens Aktiengesellschaft | Process for the recovery of metal-containing recyclables from a metal-containing valuable substances containing suspension-like mass flow |
KR101502500B1 (en) | 2011-07-01 | 2015-03-16 | 주식회사 엘지화학 | Nonaqueous electrolyte and lithium secondary battery using the same |
UA111382C2 (en) * | 2011-10-10 | 2016-04-25 | Оріон Корпорейшн | Protein kinase inhibitors |
EP2793894A4 (en) | 2011-12-23 | 2015-07-08 | Millennium Pharm Inc | Heteroaryls and uses thereof |
EP2817292B1 (en) | 2012-02-22 | 2019-12-18 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as tnap inhibitors |
EP2855472B1 (en) * | 2012-04-05 | 2016-09-14 | Boehringer Ingelheim International GmbH | Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase |
FR2992314B1 (en) | 2012-06-22 | 2015-10-16 | Sanofi Sa | NOVEL 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ONE AND 1,2,3,4-TETRAHYDRO-PYRIMIDO {1,2-A} PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE |
WO2014053533A1 (en) * | 2012-10-05 | 2014-04-10 | Sanofi | Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation |
WO2014083327A1 (en) | 2012-11-27 | 2014-06-05 | Md Pharma Ab | Adenine derivatives suitable for the treatment of (inter alia) muscular dystrophy |
GB201223265D0 (en) | 2012-12-21 | 2013-02-06 | Selvita Sa | Novel benzimidazole derivatives as kinase inhibitors |
WO2014109414A1 (en) * | 2013-01-11 | 2014-07-17 | 富士フイルム株式会社 | Nitrogen-containing heterocylic compound or salt thereof |
CN105189481A (en) * | 2013-03-13 | 2015-12-23 | 艾伯维公司 | Pyridine cdk9 kinase inhibitors |
US9242969B2 (en) * | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
BR112016016289B1 (en) | 2014-01-14 | 2023-02-07 | Takeda Pharmaceutical Company Limited | HETEROARIS AND USES THEREOF |
WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
CN107074828B (en) * | 2014-09-12 | 2020-05-19 | 诺华股份有限公司 | Compounds and compositions as RAF kinase inhibitors |
UY36294A (en) * | 2014-09-12 | 2016-04-29 | Novartis Ag | COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS |
-
2015
- 2015-01-13 BR BR112016016289-7A patent/BR112016016289B1/en active IP Right Grant
- 2015-01-13 US US14/596,052 patent/US9802960B2/en active Active
- 2015-01-13 SG SG11201604820XA patent/SG11201604820XA/en unknown
- 2015-01-13 AU AU2015206652A patent/AU2015206652A1/en not_active Abandoned
- 2015-01-13 AP AP2016009368A patent/AP2016009368A0/en unknown
- 2015-01-13 EA EA201691421A patent/EA032458B1/en not_active IP Right Cessation
- 2015-01-13 GE GEAP201514237A patent/GEP20196983B/en unknown
- 2015-01-13 MX MX2016009135A patent/MX2016009135A/en unknown
- 2015-01-13 CA CA2935867A patent/CA2935867C/en active Active
- 2015-01-13 EP EP15737173.3A patent/EP3094325B1/en active Active
- 2015-01-13 CN CN201580004591.2A patent/CN105916503B/en active Active
- 2015-01-13 JP JP2016546472A patent/JP6609258B2/en active Active
- 2015-01-13 ES ES15737173T patent/ES2908042T3/en active Active
- 2015-01-13 WO PCT/US2015/011191 patent/WO2015108861A1/en active Application Filing
- 2015-01-13 MY MYPI2016702312A patent/MY182908A/en unknown
- 2015-01-13 PE PE2016001225A patent/PE20161313A1/en unknown
- 2015-01-13 TN TN2016000270A patent/TN2016000270A1/en unknown
- 2015-01-13 KR KR1020167022343A patent/KR20160122736A/en not_active Application Discontinuation
- 2015-01-13 CR CR20160363A patent/CR20160363A/en unknown
- 2015-01-14 UY UY0001035951A patent/UY35951A/en not_active Application Discontinuation
- 2015-01-14 TW TW104101242A patent/TWI662024B/en not_active IP Right Cessation
-
2016
- 2016-07-12 DO DO2016000173A patent/DOP2016000173A/en unknown
- 2016-07-13 IL IL246755A patent/IL246755A0/en unknown
- 2016-07-13 PH PH12016501388A patent/PH12016501388A1/en unknown
- 2016-07-14 CL CL2016001805A patent/CL2016001805A1/en unknown
- 2016-08-11 EC ECIEPI201667303A patent/ECSP16067303A/en unknown
- 2016-11-09 US US15/347,334 patent/US9751854B2/en active Active
-
2017
- 2017-08-01 US US15/665,506 patent/US10538533B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110130380A1 (en) | 2009-09-04 | 2011-06-02 | Barsanti Paul A | Heteroaryl Kinase Inhibitors |
US20130102608A1 (en) | 2010-07-05 | 2013-04-25 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Bipyridyl derivatives |
WO2012009227A1 (en) | 2010-07-16 | 2012-01-19 | N30 Pharmaceuticals, Llc | Novel dihydropyridin-2(1h)-one compounds as s-nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists |
WO2014058691A1 (en) | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
Non-Patent Citations (21)
Title |
---|
"Remington's Pharmaceutical Sciences", 1980, MACK PUBLISHING CO. |
BACKER, BIOCHEM J, 2008 |
BERENBAUM M.C., J. THEOR. BIOL., vol. 114, 1985, pages 413 - 431 |
BLISS, C.I., ANN. APPL. BIOL., vol. 26, 1939, pages 585 - 615 |
CHOU T.C.TALALAY P., ADV. ENZYME REG., vol. 22, 1984, pages 27 - 55 |
DATABASE PUBCHEM [online] 21 July 2010 (2010-07-21), "AC1NE3NW", XP055357683, accession no. NCBI Database accession no. CID 4636058 * |
DATABASE PUBCHEM [online] 21 July 2010 (2010-07-21), "ZINC47212612", XP055357677, accession no. NCBI Database accession no. CID 46315357 * |
DATABASE PUBCHEM [online] 25 October 2006 (2006-10-25), "PYRROLIDINE, 1-([3,4'-BIPYRIDIN]-5-YLCARBONYL)-2-METHYL-", XP055357710, accession no. NCBI Database accession no. CID 10468190 * |
DATABASE PUBCHEM [online] 26 October 2006 (2006-10-26), "SCHEMBL4920244", XP055357662, accession no. NCBI Database accession no. CID 11566395 * |
DATABASE PUBCHEM [online] 8 February 2007 (2007-02-08), "SCHEMBL11228877", XP055357672, accession no. NCBI Database accession no. CID 13066345 * |
DELGATO ET AL., IMMUNOL REV, 2009 |
DRIVER, M. S.HARTWIG, J. F., J. AM. CHEM. SOC., vol. 118, 1996, pages 7217 - 7218 |
ENGELMAN ET AL., NATURE REVIEW GENETICS, vol. 7, 2006, pages 606 - 619 |
KONDO ET AL., NAT REV CANCER, 2005 |
LEBEGUE, N., J. MED. CHEM., vol. 48, 2005, pages 7363 - 7373 |
PETERSON, J.J.NOVIK, S.J., J RECEPT SIGNAL TRANSDUCT RES, vol. 27, 2007, pages 12 - 146 |
S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19 |
SHINTANIKLIONSKY, SCIENCE, 2004 |
TALLARIDA, R. J., J. PHARM. EXP. THERAP., vol. 319, 2006, pages 1 - 7 |
YANBACKER, BIOCHEM J, 2007 |
YIN, J., ORG. LETT., vol. 4, 2002, pages 3481 |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9988381B2 (en) | 2013-06-19 | 2018-06-05 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Five-member-heterocycle fused pyridine compounds, method of producing the same, and use thereof |
EP3012259A4 (en) * | 2013-06-19 | 2016-11-23 | Shanghai Inst Materia Medica | Five-membered heterocyclic pyridine compounds and preparation method and use thereof |
US10538533B2 (en) | 2014-01-14 | 2020-01-21 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
US10202373B2 (en) | 2014-01-14 | 2019-02-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
US9751854B2 (en) | 2014-01-14 | 2017-09-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
US9802960B2 (en) | 2014-01-14 | 2017-10-31 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
IL258662A (en) * | 2015-10-21 | 2018-06-28 | Otsuka Pharma Co Ltd | Benzolactam compounds as protein kinase inhibitors |
RU2779018C1 (en) * | 2015-10-21 | 2022-08-30 | Оцука Фармасьютикал Ко., Лтд. | Benzolactams as protein kinase inhibitors |
CN108617166A (en) * | 2015-10-21 | 2018-10-02 | 大冢制药株式会社 | Kinases inhibitor benzolactam compounds |
JP2021191757A (en) * | 2015-10-21 | 2021-12-16 | 大塚製薬株式会社 | Benzolactam compound |
JP2018532737A (en) * | 2015-10-21 | 2018-11-08 | 大塚製薬株式会社 | Benzolactam compounds |
US11001575B1 (en) | 2015-10-21 | 2021-05-11 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
TWI747846B (en) * | 2015-10-21 | 2021-12-01 | 日商大塚製藥股份有限公司 | Benzolactam compounds |
US11939321B2 (en) | 2015-10-21 | 2024-03-26 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
AU2016341520B2 (en) * | 2015-10-21 | 2020-11-12 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
JP7254127B2 (en) | 2015-10-21 | 2023-04-07 | 大塚製薬株式会社 | benzolactam compounds |
CN108617166B (en) * | 2015-10-21 | 2022-05-17 | 大冢制药株式会社 | Protein kinase inhibitor benzolactam compounds |
US10457669B2 (en) | 2015-10-21 | 2019-10-29 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
WO2017068412A1 (en) * | 2015-10-21 | 2017-04-27 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
AU2021200951B2 (en) * | 2015-10-21 | 2022-07-21 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
AU2016341520C1 (en) * | 2015-10-21 | 2021-07-22 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
WO2017140841A1 (en) | 2016-02-19 | 2017-08-24 | Sprint Bioscience Ab | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
WO2017140843A1 (en) | 2016-02-19 | 2017-08-24 | Sprint Bioscience Ab | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes |
US12030873B2 (en) | 2017-04-20 | 2024-07-09 | Otsuka Pharmaceutical Co., Ltd. | 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor |
JP7113846B2 (en) | 2017-04-20 | 2022-08-05 | 大塚製薬株式会社 | 6-pyrimidine-isoindole derivatives as ERK1/2 inhibitors |
JP2020517598A (en) * | 2017-04-20 | 2020-06-18 | 大塚製薬株式会社 | 6-pyrimidine-isoindole derivatives as ERK1/2 inhibitors |
US11142518B2 (en) | 2017-04-20 | 2021-10-12 | Otsuka Pharmaceutical Co., Ltd. | 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor |
RU2786994C2 (en) * | 2017-04-20 | 2022-12-27 | Оцука Фармасьютикал Ко., Лтд. | Pharmaceutical compound |
AU2018255935B2 (en) * | 2017-04-20 | 2022-03-17 | Otsuka Pharmaceutical Co., Ltd. | 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor |
WO2018193410A1 (en) * | 2017-04-20 | 2018-10-25 | Otsuka Pharmaceutical Co., Ltd. | 6-pyrimidin-isoindole derivative as erk1/2 inhibitor |
WO2019038389A1 (en) | 2017-08-23 | 2019-02-28 | Sprint Bioscience Ab | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds |
RU2805334C2 (en) * | 2017-08-23 | 2023-10-16 | Спринт Биосайенс Аб | Pyridylpyridones |
US11208423B2 (en) | 2017-08-23 | 2021-12-28 | Sprint Bioscience Ab | Pyridinamine-pyridone and pyrimidinamine- pyridone compounds |
WO2019038387A1 (en) | 2017-08-23 | 2019-02-28 | Sprint Bioscience Ab | Pyridylpyridone compounds |
EP4001278A1 (en) | 2017-08-23 | 2022-05-25 | Sprint Bioscience AB | Azaindolylpyridone and diazaindolylpyridone compounds |
WO2019038390A1 (en) | 2017-08-23 | 2019-02-28 | Sprint Bioscience Ab | Morpholinylpyridone compounds |
US11219618B2 (en) | 2017-08-23 | 2022-01-11 | Sprint Bioscience Ab | Pyridylpyridone compounds |
US11780858B2 (en) | 2017-08-23 | 2023-10-10 | Sprint Bioscience Ab | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds |
EP4056556A1 (en) | 2017-08-23 | 2022-09-14 | Sprint Bioscience AB | Pyridylpyridone compounds |
EP4056569A1 (en) | 2017-08-23 | 2022-09-14 | Sprint Bioscience AB | Morpholinylpyridone compounds |
TWI785102B (en) * | 2017-08-23 | 2022-12-01 | 瑞典商斯普林特生物科技公司 | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds |
TWI787335B (en) * | 2017-08-23 | 2022-12-21 | 瑞典商斯普林特生物科技公司 | Pyridylpyridone compounds |
RU2804638C2 (en) * | 2017-08-23 | 2023-10-03 | Спринт Биосайенс Аб | Pyridinaminpyridones and pyrimidinaminpyridones |
AU2018320418B2 (en) * | 2017-08-23 | 2023-04-06 | Sprint Bioscience Ab | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds |
WO2019038384A1 (en) | 2017-08-23 | 2019-02-28 | Sprint Bioscience Ab | Azaindolylpyridone and diazaindolylpyridone compounds |
EP4169581A1 (en) | 2017-08-23 | 2023-04-26 | Sprint Bioscience AB | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds |
AU2018320416B2 (en) * | 2017-08-23 | 2023-08-03 | Sprint Bioscience Ab | Pyridylpyridone compounds |
WO2019052932A1 (en) | 2017-09-18 | 2019-03-21 | Basf Se | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi |
WO2020045941A1 (en) * | 2018-08-27 | 2020-03-05 | 주식회사 대웅제약 | Novel heterocyclic amine derivative and pharmaceutical composition comprising same |
RU2760184C1 (en) * | 2018-08-27 | 2021-11-22 | Даевунг Фармасьютикал Ко., Лтд. | New heterocyclic amine derivative and a pharmaceutical composition containing it |
CN112574207A (en) * | 2019-09-30 | 2021-03-30 | 南京药石科技股份有限公司 | ERK1/2 protein kinase inhibitor and application thereof |
WO2021063335A1 (en) * | 2019-09-30 | 2021-04-08 | 南京药石科技股份有限公司 | Erk1/2 protein kinase inhibitor and use thereof |
US11801238B2 (en) | 2020-11-25 | 2023-10-31 | Deciphera Pharmaceuticals, Llc | Anti-viral activity of VPS34 inhibitors |
WO2024084363A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Use of patatin-like phospholipase domain-containing protein 3 compounds |
WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
WO2024095003A1 (en) * | 2022-11-02 | 2024-05-10 | Cerevance, Inc. | Nicotinamide derivatives for use in treating disorders associated with kcnk13 activity |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6609258B2 (en) | Heteroaryls and their use | |
AU2018222943B2 (en) | Heterocyclic compounds useful as PDK1 inhibitors | |
TWI834641B (en) | Inhibitors of plasma kallikrein and uses thereof | |
CA3042960C (en) | Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof | |
JP6374959B2 (en) | DNA-PK inhibitor | |
JP6378171B2 (en) | DNA-PK inhibitor | |
CN102131807B (en) | Pyrazolopyridine kinase inhibitors | |
JP2018150358A (en) | Tank-binding kinase inhibitor compounds | |
KR20140071361A (en) | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | |
TW201038567A (en) | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | |
EP3094326A1 (en) | Heteroaryls and uses thereof | |
JP5769733B2 (en) | Pyrazolopyridine kinase inhibitor | |
WO2023091726A1 (en) | Inhibitors of cyclin‑dependent kinase 12 (cdk12) | |
CN111247144B (en) | Azaindolylpyridone compounds and diazaindolylpyridone compounds | |
WO2024044344A1 (en) | Pyridinylsulfonamide compounds and their use in therapy | |
WO2023027948A1 (en) | Jak2 inhibitors and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15737173 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 139550140003003852 Country of ref document: IR |
|
ENP | Entry into the national phase |
Ref document number: 2935867 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016546472 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 246755 Country of ref document: IL Ref document number: 001225-2016 Country of ref document: PE Ref document number: 12016501388 Country of ref document: PH Ref document number: MX/A/2016/009135 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 39204 Country of ref document: MA |
|
ENP | Entry into the national phase |
Ref document number: 2015206652 Country of ref document: AU Date of ref document: 20150113 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015737173 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015737173 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14237 Country of ref document: GE Ref document number: NC2016/0000757 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201691421 Country of ref document: EA Ref document number: CR2016-000363 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201605347 Country of ref document: ID |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201608742 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 20167022343 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016016289 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112016016289 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160713 |